

## CUMULATIVE INDEX 2001

### Volume 85

---

January	ANTIBIOTIC THERAPY, PART II, pages 1-192
March	CARDIAC ARRHYTHMIAS, pages 193-557
May	ADVANCES IN THE PATHOPHYSIOLOGY AND TREATMENT OF PSYCHIATRIC DISORDERS: IMPLICATIONS FOR INTERNAL MEDICINE, pages 559-845
July	HEADACHES, pages 847-1099
September	POSTOPERATIVE MEDICAL COMPLICATIONS, pages 1101-1328
November	RESPIRATORY INFECTIONS, pages 1329-1634

---

*Note:* Page numbers of article titles are in **boldface** type.

Abciximab, postoperative bleeding due to, 1282  
Abdominal infections, treatment of, 121 in elderly persons, 143  
Abdominal surgery, postoperative pulmonary complications in, 1131-1132  
Abortion, septic, disseminated intravascular coagulation in, 1292  
Acamprosate, for alcohol abuse, 787  
Accessory pathways, atrioventricular node reentrant tachycardia involving, 197-204  
Acetaminophen, for headache, in pediatric patients, 1042-1043  
*I*-Acetyl-a-methadol (LAAM), for opioid abuse, 789  
Acetylcholine deficiency, in delirium, 1230  
Acid-base imbalance, in postoperative kidney dysfunction, 1249  
*Acinetobacter* pneumonia, nosocomial, 93-94, 1585  
Acquired immunodeficiency syndrome. *See* Human immunodeficiency virus infection.  
Actinomycosis, pulmonary nonresolving, 1517 radiology of, 1487  
Acupuncture, for headache, 1078-1079  
Acute tubular necrosis, postoperative assessment of, 1246-1249 causes of, 1242-1244  
detection of, 1245-1246 prevention of, 1244 treatment of, 1249-1250  
Adaptive immunity, in respiratory infection defense, 1335-1340, 1343  
Adenocarcinoma, disseminated intravascular coagulation in, 1292-1293  
Adenosine for paroxysmal supraventricular tachycardia, 1179 for supraventricular tachycardia, 212-216 for wide QRS complex tachycardia, 262, 264  
ADHD. *See* Attention deficit/hyperactivity disorder.  
Adjustment disorders, versus depression, 633-634  
Adolescent Drinking Inventory, 589  
Adrenal gland. *See* Hypothalamic-pituitary-adrenal axis.  
Adrenocorticotropin, stimulation of, in hypothalamic-pituitary-adrenal axis testing, 1314-1315  
Affect, inappropriate, in schizophrenia, 666  
Afterdepolarization delayed, in ventricular tachycardia, 270 early, in polymorphic ventricular tachycardia, 328-329  
Agammaglobulinemia, pneumonia risk in, 1341

AIDS. *See* Human immunodeficiency virus infection.

Alcohol use and abuse, 783-787, 1191-1212  
 clinical features of, 590  
 consequences of, 784-785  
 definition of, 1191-1193  
 diagnosis of, 587-591  
 emergency presentation of, 784  
 epidemiology of, 1193-1194  
 headache due to, 925-926  
 in bipolar disorder, 654  
 pathophysiology of, 783  
 pneumonia risk in, 1341-1342  
 postoperative withdrawal syndrome in  
   clinical features of, 1200-1202  
   delirium tremens in, 1202  
   differential diagnosis of, 1197-1198  
   early uncomplicated, 1200  
   hallucinosis in, 1201  
   physiology of, 1199  
   prolonged, 1202  
   seizures in, 1200  
   sequela of, 1202-1203  
   severity of, 1200  
   time course for, 1199  
   treatment of, 1203-1207  
 preoperative instructions in, 1197  
 prevention of, 1194-1197  
 relapse from, 786-787  
 screening for, 1194-1196  
 treatment of, 785-787  
 withdrawal from, 783-786

Allergic granulomatous angiitis, versus pneumonia, 1523

Almotriptan  
 for migraine, 962, 963  
 structure of, 955

Alopecia, antibiotic-induced, 179

Alprazolam  
 for generalized anxiety disorder, 705  
 for social anxiety disorder, 722

Alternative therapies, for headache, 1077-1084  
 acupuncture, 1078-1079  
 herbal, 1081-1082  
 mind-body techniques in, 1079-1080  
 nutritional, 1080-1081  
 physical approaches to, 1082

Alveolar hemorrhage, in systemic lupus erythematosus, versus pneumonia, 1423

Alveolar macrophages, in respiratory infection defense, 1333-1335, 1445

Alzheimer's disease, 803-817  
 depression in, 809-810  
 psychosis in, 810-813  
 treatment of, 805-808  
 versus dementia with Lewy bodies, 804, 813

Amantadine  
 for influenza prophylaxis, 1454, 1539-1541

neurologic side effects of, 161

American Academy of Neurology, migraine practice guidelines of, 873

American College of Cardiology, pacing guidelines of, 369-374

American Heart Association, pacing guidelines of, 369-374

American Thoracic Society  
 pneumonia prediction rules and practice guidelines of, 1400-1401, 1495, 1499-1501  
 pneumonia severity criteria of, 1419-1420

American trypanosomiasis (Chagas' disease), ventricular tachycardia in, 299

Amikacin, for nosocomial pneumonia, 102

Aminoglycosides  
 for elderly persons, 141  
 for *Pseudomonas aeruginosa* infections, 36-38  
 resistance to, 21-23, 36-37  
 nephrotoxicity of, 173, 175  
 neurologic side effects of, 161

Amiodarone  
 for arrhythmias, perioperative, 1175-1176  
 for atrial fibrillation, 234-235  
 for supraventricular tachycardia, 214, 217  
 for ventricular tachycardia  
   in elderly persons, 542  
   in ischemic heart disease, 272-277, 280-283  
   polymorphic, 331  
 for wide QRS complex tachycardia, 263-264  
 long-term use of, perioperative recommendations for, 1120  
 proarrhythmia monitoring and, 520  
 pulmonary infiltration due to, versus pneumonia, 1524-1525  
 ventricular proarrhythmia due to, 515

Amitriptyline, for migraine  
 in pediatric patients, 1049  
 with behavioral treatment, 1066

Amnesia, in alcoholism, 785

Amniotic fluid embolism, disseminated intravascular coagulation in, 1292

Amoxicillin  
 for *Helicobacter pylori* infections, 120  
 for pneumonia, *Streptococcus pneumoniae*, 1374-1375

Amoxicillin-clavulanate, for staphylococcal infections, 6

Amphetamines, abuse of, 780-783

Amphotericin B, hypotension due to, 163

Ampicillin  
 for animal bite infections, 119  
 for listeriosis, 123

- for pneumonia, *Streptococcus pneumoniae*, 1374-1376
- Amygdala, dysfunction of, in anxiety disorders, 569-570
- b-Amyloid deposition, in Alzheimer's disease, 808
- Anaerobic infections
  - clindamycin for, 128
  - metronidazole for, 129
  - pneumonia, 1585
    - community-acquired, 53
    - nosocomial, 95-97
    - radiology of, 1467
- Analgesics, overuse and misuse of, in headache, 1058-1060, 1067-1068
- Anaphylactic reactions, antibiotic-induced, 157, 159
- Anemia, antibiotic-induced, 152, 154-155
- Anesthesia
  - anticoagulation and, 1113-1114
  - pulmonary complications due to, 1132
- Aneurysm, cerebral
  - headache in, 873-878
    - emergency department handling of, 976-977
    - postoperative stroke in, 1271
- Angina pectoris, headache in, 1088-1089
- Angiography, in headache, 878
- Angioplasty, coronary, before noncardiac surgery, 1159
- Angiotensin-converting enzyme inhibitors
  - for congestive heart failure, 1164-1166
  - for hypertension, 1154
  - for myocardial infarction, 1160
  - for ventricular tachycardia, in ischemic heart disease, 272
  - long-term use of, perioperative recommendations for, 1121-1122
- Angiotensin II receptor blockers, long-term use of, perioperative recommendations for, 1121-1122
- Annexin, antibodies to, bleeding in, 1283-1284
- Antacids, nosocomial pneumonia associated with, 1553-1554
- Anthrax, treatment of, 118
- Antiangiinal drugs, long-term use of, perioperative recommendations for, 1120
- Antiarrhythmic drugs. *See also specific drugs.*
  - long-term use of, perioperative recommendations for, 1120-1121
  - proarrhythmia due to. *See Proarrhythmia.*
- Antibiotics. *See also specific antibiotics and infections.*
  - costs of
    - for elderly persons, 135
    - in pneumonia, 64, 66-69
  - for elderly persons, 133-147
  - for gastrointestinal infections, 120-123
  - for osteomyelitis, 117-118
  - for pneumonia
    - community-acquired, 43-78
    - guidelines for, 1501-1506
    - switch therapy in, 1429-1434
    - nosocomial, 79-113
    - ventilator-associated
      - inappropriate, 1566, 1571-1572
      - resistance and, 1566-1567
      - withholding pending culture results, 1569-1570
  - for pseudomonal infections, 19-42
  - for sinopulmonary infections, 116-117
  - for skin infections, 118-120, 142-143
  - for staphylococcal infections, 1-17
  - for urinary tract infections, 123, 142
  - new uses for, 125-132
  - nosocomial pneumonia associated with, 1554
  - oral, 115-123
    - switching from intravenous therapy, 70, 1429-1434
  - resistance to, 115-116
    - in pneumonia
      - community-acquired, 58-59
      - nosocomial, 1589-1590
      - ventilator-associated, 1566-1567
  - Pseudomonas aeruginosa*, 19-40
  - Staphylococci*, 3-5, 10, 127
  - Staphylococcus aureus*, 2-5
  - Streptococcus pneumoniae*, 1367-1379, 1503-1504
  - side effects of, 149-185
    - cardiac, 163, 169
    - class, 149-150
    - gastrointestinal, 170-172
    - hematologic, 150-155
    - hepatic, 171, 173-174
    - hypersensitivity, 153, 156-160
    - in pneumonia, 60-63
    - individual, 149-150
    - metabolic, 175, 177-178
    - nephrotoxic, 173, 175-176
    - neurologic, 160-162, 164-167
    - pulmonary, 162-163, 168
  - Antibody(ies), heparin, thrombocytopenia due to, 1283-1284, 1289, 1305-1307
  - Anticoagulants
    - for atrial fibrillation, 231-233, 531-532
    - for stroke, 1272-1273
    - perioperative, 1109-1116
      - anesthesia safety and, 1113-1114
      - bleeding risks and, 1109-1110, 1282-1286
    - discontinuation of, thrombosis risks in, 1111-1112
    - pharmacokinetics of, 1112-1113
    - recommendations for, 1114-1115

Anticoagulants (*Continued*)  
 stroke due to, 1270

Antidepressants  
 action of, 563–564  
 for attention deficit/hyperactivity disorder, 768–769  
 for bipolar disorder, 657  
 for depression, 564, 635–639, 809–810  
 for generalized anxiety disorder, 705–706  
 for migraine  
   in pediatric patients, 1049–1050  
   with behavioral treatment, 1066  
 for social anxiety disorder, 723–724  
 long-term use of, perioperative recommendations for, 1125

Antidiuretic hormone, inappropriate secretion of, postoperative, 1247–1248

Antidromic atrioventricular node reentrant tachycardia, 197

Antiepileptics, long-term use of, perioperative recommendations for, 1124

Antifungal agents, for elderly persons, 144

Antigen recognition and processing, in respiratory infection defense, 1336

Antigen studies, for pneumonia diagnosis, 1387–1388

Antihypertensives, long-term use of, perioperative recommendations for, 1121–1122

Antikindling agents, for alcohol withdrawal, 785–786

Antioxidants, for Alzheimer's disease, 807

Antiparkinson drugs, 1125

Antipsychotic agents  
   for Alzheimer's disease, 810–813  
   for bipolar disorder, 655–656, 658  
   for schizophrenia, 674–676  
   long-term use of, perioperative recommendations for, 1126

Antiretroviral agents, gastrointestinal side effects of, 170

Antisocial personality disorder, 828–829

Antithrombin III deficiency, postoperative stroke in, 1266

Antithyroid drugs, long-term use of, perioperative recommendations for, 1125

Antiviral agents, for elderly persons, 144

Anxiety disorder, syncope in, 441–442

Anxiety disorders  
   classification of, 585–586  
   depression with, 633  
   diagnosis of, 584–587  
   economic impact of, 584  
   generalized, 691–710  
     clinical features of, 701  
     comorbidity with, 696–697, 702  
     concept of, 691–693  
     costs of, 702–703  
     course of, 701  
     definition of, 585  
     diagnosis of, 586  
     epidemiology of, 692, 694–697  
     imaging in, 700  
     impairment in, 702–703  
     pathophysiology of, 697–700  
     risk factors for, 695–696  
     treatment of, 703–706  
   imaging in, 567–569  
   in medical illness, 586–587  
   pathophysiology of, 564–570  
   social. *See* Social anxiety disorder.  
   treatment of, 569–570  
   underdetection of, 586  
   versus attention deficit/hyperactivity disorder, 761–762  
   versus normal anxiety, 586

Aplastic anemia, antibiotic-induced, 152, 155

Aprotinin, for postoperative bleeding, 1287–1288

Ardeparin, for deep vein thrombosis prevention, 1104

Argatroban, for heparin-induced thrombocytopenia, 1284, 1305–1306

Aromatherapy, for headache, 1081

Arrhythmia(s). *See also specific arrhythmias.*  
 antibiotic-induced, 163, 169  
 implantable cardiac defibrillators for. *See* Implantable cardiac defibrillators.  
 perioperative, 1171–1189  
   atrial flutter and atrial fibrillation, 1173–1178  
   atrial premature contractions, 1176  
   bradycardia, 1172–1173  
   in cardiac surgery, 1173–1174  
   in thoracic surgery, 1174–1175  
   incidence of, 1171–1172  
   multifocal atrial tachycardia, 1179–1180  
   narrow-complex tachycardia, 1178–1179  
   paroxysmal supraventricular tachycardia, 1178–1179  
   risk factors for, 1172–1176  
   significance of, 1171–1172  
   sinus tachycardia, 1172, 1176  
   ventricular fibrillation, 1180–1181  
   ventricular premature contractions, 1180  
   ventricular tachycardia, 1180–1181  
   wide-complex tachycardia, 1181

Arrhythmogenic right ventricular dysplasia, tachycardia in, 296–298

Arteriovenous malformations, versus migraine, 872–873

Arteritis, giant cell (temporal), headache in, 879–882, 980, 1087–1088

Arthropathy, antibiotic-induced, 177, 179

Arthroplasty, thrombosis prophylaxis after, 1101-1107

Aspartame, as migraine trigger, 931

Aspergillosis, pulmonary

- nonresolving, 1516
- nosocomial, 1586
- radiology of, 1485-1487

Aspiration, for pneumonia diagnosis

- thoracic, 1390-1391
- tracheal, 1389-1390

Aspiration pneumonia

- in elderly persons, 1444
- treatment of, 53
- versus community-acquired pneumonia, 1525

Aspirin

- for atrial fibrillation, 231, 531-532
- for myocardial infarction, 1160
- for stroke, 1273
- prophylactic, in carotid endarterectomy, 1268
- long-term use of, perioperative recommendations for, 1119
- postoperative bleeding due to, 1281

Asthma, drugs for, long-term use of, perioperative recommendations for, 1122-1123

Ataxia, cerebellar, antibiotic-induced, 165

Atenolol

- for alcohol withdrawal, 1206
- for myocardial ischemia prevention, 1157
- for social anxiety disorder, 722
- for supraventricular tachycardia, 214, 216
- for syncope, 448

Atherosclerosis

- in diabetes mellitus, postoperative considerations in, 1216-1217
- myocardial ischemia in, perioperative, 1155

Atrial fibrillation and atrial flutter, 225-244

- anticoagulant therapy for, perioperative recommendations for, 1111-1112
- begets atrial fibrillation, 229
- causes of, 225-227
- chronic, 227, 484
- clinical assessment of, 229-230
- epidemiology of, 225-227
- in elderly persons, 529-532
- in Wolff-Parkinson-White syndrome, 199, 218-219
- natural history of, 227-228
- paroxysmal, 227, 483
- pathophysiology of, 228-229
- perioperative, 1173-1178
- stroke in, 1264-1265
- persistent, 227
- treatment of, 230-239
- atrial remodeling prevention in, 238-239

catheter ablation, 479-484

nonpharmacologic, 235-238

pacemaker, 236, 239, 386-389

pharmacologic, 233-234

sinus rhythm restoration and maintenance in, 231-239

thromboembolic prophylaxis in, 231

vagally mediated, pacemaker in, 386-389

Atrial premature beats

- in elderly persons, 527-529
- perioperative, 1176

Atrial tachycardia, 201, 203, 205-207

- as proarrhythmia, 511-513
- catheter ablation of, 477-479
- focal, 478
- in elderly persons, 527-529
- incisional, 479
- multifocal, 206, 208
- perioperative, 1179-1180
- pacemaker in, 399-400

Atrioventricular block

- in elderly persons, 533-534
- pacemaker in, 370, 390-400
- perioperative, 1181-1182

Atrioventricular dissociation, in tachycardia, 253-255

Atrioventricular junction, catheter ablation of, 490-491

Atrioventricular node reentrant tachycardia, 194-197

- catheter ablation of, 484-486, 489-490
- mediated by accessory pathways, 197-204

Atrium, remodeling of, in atrial fibrillation, 229, 238-239

Attention deficit, in delirium, 1231

Attention deficit/hyperactivity disorder, 757-777

- classification of, 759-760
- clinical features of, 759-760
- comorbidity with, 762
- differential diagnosis of, 761-762
- epidemiology of, 758-759
- evaluation of, 761
- historical overview of, 757-758
- medical illness with, 762
- psychiatric interview in, 763
- psychologic testing in, 764-766
- rating scales for, 763-764
- Tourette syndrome with, 744
- treatment of, 766-773
- behavioral, 771-773
- in adults, 772-773
- pharmacologic, 766-771

Atypical pneumonia syndrome, 1349-1365.

- See also specific pathogens.*
- clinical features of, 1351
- infections in, 1354-1356
- diagnosis of, 1356-1358
- epidemiology of, 1351-1354

Atypical pneumonia syndrome (*Continued*)  
 historical perspective of, 1350–1351  
 nonresolving, 1514  
 prognosis for, 1358–1359  
 treatment of, 1358–1359, 1502–1503  
 unknown pathogens in, 1354

AUDIT questionnaire, for alcohol use screening, 1194–1196

Aura  
 migraine with, 898–901, 945, 948  
 migraine without, 898–901, 951  
 versus tension-type headache, 903–906

Automatic information processing, in obsessive-compulsive disorder, 740

Automaticity, of pacemakers, 404–406

Autonomic dysfunction  
 in anxiety disorders, 699–701  
 in cluster headache, 998–999  
 in SUNCT syndrome, 1007  
 syncope in. *See* Syncope, in autonomic dysfunction.

Avoidant personality disorder, 829

Azithromycin  
 for elderly persons, 139  
 for pneumonia, 69  
 community-acquired, 1505  
*Streptococcus pneumoniae*, 1374–1375

Azlocillin, for *Pseudomonas aeruginosa* infections, 20–21, 25

Azotemia, in postoperative kidney dysfunction, 1248

Aztreonam  
 for elderly persons, 138  
 for nosocomial pneumonia, 102  
 for *Pseudomonas aeruginosa* infections, 24  
 pharmacokinetics of, 24  
 resistance to, 21–22

B lymphocytes, in respiratory infection defense, 1331–1332, 1339–1340

Bacitracin, for skin infections, 118

*Bacteroides* pneumonia  
 community-acquired, 53  
 nosocomial, 95–96

Barbiturates, for alcohol withdrawal, 1206–1207

Basal ganglia, pathology of, in schizophrenia, 671–672

Basilar artery migraine, 907

BATHE mnemonic, for anxiety screening, 703

Behavioral therapy  
 for alcohol abuse, 1204  
 for attention deficit/hyperactivity disorder, 771–773  
 for headache, 1055–1075  
 activity participation in, 1069  
 advantages of, 1055–1056

analgesic overuse control in, 1067–1068

analgesic use evaluation for, 1058–1060

biofeedback in, 1063–1065

chronic daily, 1058–1059, 1064

cognitive-behavioral analysis for, 1056

comorbid psychiatric disorder evaluation for, 1061–1063

compliance issues in, 1069–1070

disability impact evaluation for, 1063

factors underlying, 1068–1069

future of, 1070–1071

in multidisciplinary, 1068

migraine, 1063–1067

multiaxial behavioral assessment for, 1057–1063

pharmacotherapy with, 1065–1067

posttraumatic, 1065

relaxation therapy in, 1063–1065

stress assessment for, 1060

tension-type, 1065–1067

for psychiatric disorders, 619

for social anxiety disorder, 724

Behavioral triggers, of migraine, 912, 918–920

Benzodiazepine(s)  
 for alcohol withdrawal, 785, 1205–1206  
 for delirium, 1236  
 for generalized anxiety disorder, 704–705  
 for social anxiety disorder, 722  
 long-term use of, perioperative recommendations for, 1126

Benzodiazepine complex, abnormalities of, in anxiety disorders, 698

Benztropine mesylate, for migraine, 982

Bereavement, versus depression, 633

Beta-blockers  
 for alcohol withdrawal, 1206  
 for atrial fibrillation, 1174  
 for congestive heart failure, 1165  
 for hypertension, 1154  
 for long Q-T syndrome, 336  
 for migraine, 956, 1050–1051  
 for myocardial infarction, 1160  
 for myocardial ischemia prevention, 1157, 1159  
 for social anxiety disorder, 723  
 for supraventricular tachycardia, 214–217  
 for syncope, 469  
 for ventricular tachycardia, in elderly persons, 541–542  
 long-term use of, perioperative recommendations for, 1120–1121

Beta-lactam antibiotics. *See also* Penicillin(s); specific antibiotics.  
 anaphylactic reactions to, 157  
 for elderly persons, 136–138  
 for *Staphylococcus aureus* infections, 5–7

nephrotoxicity of, 175  
resistance to, 2-3, 10

Beta-lactamase inhibitors, for elderly persons, 138-139

Biapenem, for *Pseudomonas aeruginosa* infections, 30, 33

Bifascicular block  
pacemaker in, 370  
perioperative, 1182

Biofeedback, for headache, 1063-1065, 1079-1080

Biofilm, antibiotic resistance in, *Staphylococcus epidermidis*, 11

Biopsy  
brain, postoperative stroke in, 1271  
lung, in pneumonia, 1391

Bipolar disorder, 635-662  
causes of, 647  
clinical features of, 647-652  
depression in, 649-650, 657  
diagnosis of, 652-655  
epidemiology of, 646-647  
genetics of, 645-646  
illnesses with, 654-655  
mania in, 647-649, 655-656  
mixed episodes in, 650-652, 655-656  
psychotherapy for, 622  
rapid cycling in, 652  
treatment of, 655-658

type I, diagnosis of, 652-653  
type II, diagnosis of, 653  
versus attention deficit/hyperactivity disorder, 761  
versus schizophrenia, 668

Bisoprolol, for myocardial ischemia prevention, 1157

Bites, animal, treatment of, 119-120

Blastomycosis, pulmonary  
nonresolving, 1515  
radiology of, 1484

Bleeding. *See also* Hemorrhage.  
antibiotic-induced, 152-153, 155  
postoperative, 1277-1310  
anticoagulant-induced, 1282-1288  
assessment of, 1280-1281  
case studies of, 1298-1308  
hemostasis physiology and, 1277-1280  
in acquired factor VIII inhibitors, 1298-1302  
in disseminated intravascular coagulation, 1290-1296  
in fibrinolysis, 1295, 1297  
in heparin therapy, 1302-1307  
in prostatectomy, 1289-1290  
in thrombocytopenia, 1307-1308  
platelet inhibitors causing, 1281-1282  
transfusion-related, 1288-1289  
uremic, 1297  
uterine, 1290  
wound management in, 1297

risks of, in surgical procedures, anticoagulation and, 1109-1110, 1114

Blindness, antibiotic-induced, 162, 167

Blood culture, for pneumonia diagnosis, 1386, 1449-1450

Blood transfusions, postoperative bleeding related to, 1288-1289

Boils, treatment of, 118

Borderline personality disorder, 825-826, 1062-1063

Bradycardia  
as proarrhythmia, treatment of, 522-523  
drug-induced, 511  
in elderly persons, 532-535  
pacing for, implantable cardiac defibrillator in, 350-351  
perioperative, 1172-1173

Brain  
aneurysm of  
headache in, 873-878, 976-977  
postoperative stroke in, 1271  
biopsy of, postoperative stroke in, 1271  
computed tomography of, in syncope, 437

injury of  
disseminated intravascular coagulation in, 1293  
headache in, 978. *See also* Posttraumatic headache.

tumors of  
headache in, 978-979  
postoperative stroke in, 1269  
vasculitis of, postoperative stroke in, 1267, 1270

venous thrombosis in, postoperative stroke in, 1267

Bretymium, for wide QRS complex tachycardia, 264

Brief Social Phobia Scale, in social anxiety disorder, 714, 716

British Thoracic Society, pneumonia prediction rules and practice guidelines of, 1400, 1495-1496

Brofaromine, for social anxiety disorder, 722-723

Bromocriptine  
for menstrual migraine, 1024-1025  
long-term use of, perioperative recommendations for, 1125

Bronchioalveolar carcinoma, versus pneumonia, 1520

Bronchiolitis obliterans organizing pneumonia, 1519-1520

Bronchoalveolar lavage, for pneumonia diagnosis, ventilator-associated, 1574-1576

Bronchopneumonia, radiology of, 1465-1467

Bronchoscopy  
for pneumonia diagnosis, 1390-1391

Bronchoscopy (Continued)

- ventilator-associated, 1574–1576
- nosocomial pneumonia risk in, 1556
- Brugada's syndrome, 294–295, 323–324
- Bundle-branch block
  - in elderly persons, 534
  - in idiopathic cardiomyopathy, ventricular tachycardia in, 284–286
  - wide QRS complex tachycardia in, 258, 260–261
- Bupropion
  - for attention deficit/hyperactivity disorder, 766–767, 769
  - for depression, 636
  - for smoking cessation, 791
- Buspirone
  - for generalized anxiety disorder, 705
  - for social anxiety disorder, 723–724
- Butorphanol, for cluster headache, 982
- Butterbur root, for headache, 1081

Caffeine
 

- as migraine trigger, 923–925
- for headache, 1081
- for hypnic headache syndrome, 1009, 1011

CAGE questionnaire, for alcohol use screening, 589–591, 1194–1196

Calcium channel blockers, long-term use of, perioperative recommendations for, 1120–1121

*Campylobacter* gastroenteritis, treatment of, 122

Canadian guidelines, for community-acquired pneumonia, 1497–1499

Cancer
 

- disseminated intravascular coagulation in, 1292–1293
- hypercoagulopathy in, postoperative stroke in, 1267
- lung, versus pneumonia, 1520–1522

*Candida albicans* pneumonia, nosocomial, 1586

Carbamazepine
 

- for alcohol withdrawal, 785–786, 1206
- for bipolar disorder, 655–658
- for cranial neuralgia, 983

Carbapenems
 

- for elderly persons, 138
- for nosocomial pneumonia, 101–102
- for *Pseudomonas aeruginosa* infections, 29–33
- for *Streptococcus pneumoniae* pneumonia, resistance to, 1368

Carbidopa/levodopa, perioperative recommendations for, 1125

Carbuncles, treatment of, 118

Cardiac arrest. *See also* Mortality

- antiarrhythmic agent-induced, 510–511

Cardiac arrhythmias. *See also specific arrhythmias.*

- atrial fibrillation. *See* Atrial fibrillation and atrial flutter.
- catheter ablation of. *See* Catheter ablation.
- defibrillators for. *See* Implantable cardiac defibrillators.
- in elderly persons, 527–550
- pacing for. *See* Pacemakers.
- proarrhythmia, 503–526
- supraventricular tachycardia. *See* Supraventricular tachycardia.
- syncope in. *See* Syncope.
- ventricular tachycardia. *See* Ventricular tachycardia.
- wide QRS complex tachycardias, 245–266

Cardiac cephalgia, 1088–1089

Cardiac risk index, preoperative, 1134

Cardiomyopathy
 

- dilated
  - pacemaker in, 373
  - ventricular tachycardia in, 311–312, 495–496
- hypertrophic
  - pacemaker in, 372, 379–382
  - ventricular tachycardia in, 286–288, 310–311
- idiopathic, ventricular tachycardia in, 284–286
- progressive, arrhythmogenic right ventricular dysplasia in, 296–298

Cardiopulmonary risk index, preoperative, 1134

Cardiovascular disease
 

- antibiotic-induced, 163, 169
- drugs for, long-term use of, perioperative recommendations for, 1120–1122
- perioperative, 1151–1168. *See also* Arrhythmia(s), perioperative.
- congestive heart failure, 1161–1166
- hypertension, 1151–1154
- hypotension, 1153, 1155
- myocardial ischemia and myocardial infarction, 1155–1161
- stroke in, postoperative, 1264–1265

Cardiovascular surgery. *See also* Coronary artery bypass graft surgery.

- arrhythmias related to, 1173–1174
- postoperative stroke in, 1267–1269

Cardioversion
 

- for atrial fibrillation, 231–233, 1177
- for proarrhythmia, 522
- for wide QRS complex tachycardia evaluation, 263

Carotid arteries
 

- dissection of, headache in, 977
- endarterectomy of, postoperative stroke in, 1267–1269, 1271

injury of, headache in, 1089–1090  
ultrasonography of, in syncope, 437

Carotid sinus massage  
for paroxysmal supraventricular tachycardia, 1179  
for supraventricular tachycardia, 213  
for syncope evaluation, 440–441

Carotid sinus syndrome, pacemaker in, 372, 390

Carvedilol, for ventricular tachycardia, in elderly persons, 541–542

Catecholaminergic polymorphic ventricular tachycardia, 296, 323, 333

Catheter ablation, 473–502  
of atrial fibrillation and atrial flutter, 230, 235–236, 479–484  
of atrial tachycardia, 477–479, 529  
of atrioventricular junction, 490–491  
of atrioventricular nodal reentrant tachycardia, 484–486, 489–490  
of concealed pathway arrhythmias, 484–488  
of preexcitation syndrome arrhythmias, 484–488  
of supraventricular tachycardia, 218, 220  
of ventricular tachycardia  
  bundle-branch reentrant, 493  
  economic considerations in, 496  
  idiopathic, 492–493  
  in elderly persons, 543  
  nonidiopathic, 493–496  
of Wolff-Parkinson-White syndrome arrhythmias, 484–486  
procedure for, 474–477

Catheter-related sepsis, in nutritional support, 1260

Cefazolin, for staphylococcal infections, 6–7

Cefepime, for nosocomial pneumonia, 101–103

Cefoperazone, for *Pseudomonas aeruginosa* infections, 24, 26–28

Cefsulodin, for *Pseudomonas aeruginosa* infections, 24, 26–28

Ceftazidime, for *Pseudomonas aeruginosa* infections, 24, 26–28

Ceftriaxone, for pneumonia, 69

Celecoxib, long-term use of, perioperative recommendations for, 1119–1120

Cellulitis, treatment of, 119

Center for Epidemiological Studies—Depression screen, 582–583

Centers for Disease Control, pneumonia practice guidelines of, 1497

Cephalexin, for skin infections, 118

Cephalosporins  
  for elderly persons, 137–138  
  for pneumonia  
    community-acquired, 66, 69  
    nosocomial, 96, 99–101

*Streptococcus pneumoniae*, 1374–1376  
for *Pseudomonas aeruginosa* infections, 24, 26–28  
resistance to, 21–22, 26–27

for *Streptococcus pneumoniae* pneumonia, resistance to, 1368–1373

gastrointestinal side effects of, 170  
hematologic effects of, 152

Cerebellar ataxia, antibiotic-induced, 165

Cerebellar atrophy, syncope in, 463

Cerebritis, headache in, 979

Cerebrospinal fluid  
  examination of, in headache, 876–877  
  hypotension of, headache in, 980

Cervicogenic headache, 988–989

Cervicothoracic ganglionectomy, for long Q-T syndrome, 336

Chagas' disease, ventricular tachycardia in, 299

Chemotherapy, pneumonia risk in, 1341

Chinese restaurant syndrome, 928–929

Chiropractic, for headache, 1082

*Chlamydia pneumoniae* pneumonia, community-acquired, 46, 1349  
  clinical features of, 1351  
  coinfection with, 1354–1356  
  diagnosis of, 1357, 1387  
  differential diagnosis of, 48–49  
  epidemiology of, 1352–1354  
  nonresolving, 1514  
  prognosis for, 1358–1359  
  treatment of, 1358–1359, 1502–1503  
  empiric, 53  
  monotherapy versus combination therapy in, 63, 65–66

Chloramphenicol  
  for *Streptococcus pneumoniae* pneumonia, resistance to, 1368  
  hematologic effects of, 152  
  new uses for, 130  
  resistance to, 3, 10

Chlordiazepoxide, for alcohol withdrawal, 1205

Chloride, fractional excretion of, in perioperative kidney dysfunction, 1246–1247

Chlorpromazine, for schizophrenia, 674

Chocolate, as migraine trigger, 926–927

Cholecystokinin, abnormalities of, in anxiety disorders, 567, 699

Cholera, treatment of, 122

Cholestasis, antibiotic-induced, 173–174

Cholestyramine, long-term use of, perioperative recommendations for, 1122

Cholinesterase inhibitors, for Alzheimer's disease, 805–807

Chronic granulomatous disease, pneumonia risk in, 1341–1342

Chronic obstructive pulmonary disease, postoperative pulmonary complication risk in, 1131

Churg-Strauss syndrome, versus pneumonia, 1523

Cigarette smoking, 790-791  
as migraine trigger, 922-923  
in schizophrenia, 679  
screening for, 591-592

Cimetidine, triptan interactions with, 963

Ciprofloxacin  
for abdominal infections, 121  
for pneumonia, community-acquired, 1504-1505  
for *Pseudomonas aeruginosa* infections, 21-22, 33-35, 119  
for skin infections, 118  
for staphylococcal infections, 6  
for *Streptococcus pneumoniae* pneumonia, 1368  
minimal inhibitory concentration drift of, 59  
neurologic side effects of, 161  
resistance to, 33-34, 1368

Citalopram, for depression, 636

Clarithromycin  
for elderly persons, 139  
for *Helicobacter pylori* infections, 120  
for *Streptococcus pneumoniae* pneumonia, 1374  
gastrointestinal side effects of, 170

Clinafloxacin, for *Pseudomonas aeruginosa* infections, 35-36

Clindamycin  
for skin infections, 118  
for staphylococcal infections, 6  
for *Streptococcus pneumoniae* pneumonia, 1368-1369  
neurologic side effects of, 161  
new uses for, 128-129  
resistance to, 10, 1368-1369

Clinical pathways, for pneumonia care, 1434

Clonazepam, for social anxiety disorder, 722

Clonidine  
for alcohol withdrawal, 1206  
for attention deficit/hyperactivity disorder, 767  
for hypertension, 1154  
for opioid withdrawal, 788  
for syncope, 470  
for Tourette syndrome, 749  
long-term use of, perioperative recommendations for, 1122  
withdrawal from, hypertension in, 1152

Clopidogrel, postoperative bleeding due to, 1281-1282

*Clostridium difficile* infections, antibiotic-induced, 67, 121, 171-172

Clozapine, for schizophrenia, 675

Cluster headache, 850, **997-1016**  
aggravating factors for, 855  
chronic, 998  
epidemiology of, 997  
episodic, 998  
impact of, 891  
treatment of, emergency, 982-983  
versus hemicrania continua, 1004-1006, 1010  
versus hypnic headache syndrome, 1009-1011  
versus paroxysmal hemicrania, 1000-1004, 1010  
versus SUNCT syndrome, 1006-1008, 1010

Cluster-migraine syndrome, 1008-1009

Cluster-tic syndrome, 1008-1009

Coagulation factors, requirements of, for adequate hemostasis, 1296

Coagulopathy. *See also* Bleeding, postoperative; Hypercoagulability; Thrombosis.  
anticoagulant therapy for, perioperative recommendations for, 1112  
stroke in, 1270

Cocaine abuse, 780-783

Coccidioidomycosis, pulmonary  
nonresolving, 1516  
radiology of, 1482-1484

Cockcroft-Gault formula, for kidney function evaluation, 1245-1246

Cognitive behavior therapy  
for generalized anxiety disorder, 703-704  
for obsessive-compulsive disorder, 741  
for psychiatric disorders, 619-620

Cognitive-behavioral treatment. *See* Behavioral therapy.

Cognitive coping strategies, for schizophrenia, 623

Cognitive dysfunction  
in delirium, 1231  
in dementia. *See* Dementia.  
in schizophrenia, 666-667

Cognitive rehabilitation, for schizophrenia, 623

Cold therapy, for headache, 1082

Colestipol, long-term use of, perioperative recommendations for, 1122

Colonization, of pneumonia organisms, in elderly persons, 1444

Common variable immunodeficiency, pneumonia risk in, 1341

Community-acquired pneumonia. *See* Pneumonia, community-acquired.

Complementary therapies. *See* Alternative therapies.

Computed tomography  
in headache, 866-867, 870-871, 875-876, 878  
in pediatric patients, 1047  
migraine, 871-872, 902-903

- in pneumonia, community-acquired, 1382
- in syncope, 437
- Concussion, headache after, 978, **987-996**
- Conduction disorders
  - implantable cardioverter defibrillators in, perioperative management of, 1183
  - pacemakers in. *See* **Pacemakers**.
  - perioperative
    - incidence of, 1171-1172
    - risk factors for, 1172-1176
    - sinus node dysfunction, 1181-1182
- Confusion Assessment Method, in delirium, 1232-1233
- Congestive heart failure
  - pacemaker in, 382-386
  - perioperative, 1161-1166
    - compensated, noncardiac surgery in, 1163
    - diagnosis of, 1162-1163
    - incidence of, 1161
    - long-term medications for, 1163-1165
    - pathophysiology of, 1161-1162
    - risk factors for, 1162
    - timing of, 1162
    - treatment of, 1165-1166
- Conjunctivitis, antibiotic-induced, 179
- Contraceptives, hormonal, migraine related to, 1028-1030
- Contrast agents, kidney dysfunction related to, 1242
- Coronary angioplasty, before noncardiac surgery, 1159
- Coronary artery(ies), triptan effects on, 964-965
- Coronary artery bypass graft surgery before noncardiac surgery, 1158-1159
  - diabetes mellitus in, postoperative management in, 1221-1222
  - postoperative stroke in, 1268-1269
- Coronary artery disease, ventricular tachycardia in, 270-283, 312-315
  - bypass surgery for, 543
  - polymorphic, 332-333
- Corticosteroids
  - perioperative significance of, **1311-1317**
    - case study of, 1311-1312
    - hypothalamic-pituitary-adrenal axis suppression and, 1313-1315
    - physiology of, 1312
    - surgical stress and, 1312-1313
  - pneumonia due to, 1341
- Corticostriatopallidothalamic circuitry, abnormalities of, 735
  - in obsessive-compulsive disorder, 735, 738-739
- in Tourette syndrome, 744-747
- Costs, of antibiotics for elderly persons, 135
- in pneumonia, 64, 66-69
- Cosyntropin test, for hypothalamic-pituitary-adrenal axis function, 1314-1315
- Cough headache, 1085-1086
- Creatinine clearance, for kidney function evaluation, 1245-1246
- Cryoprecipitate
  - for disseminated intravascular coagulation, 1294
  - for postoperative bleeding, 1288
- Cryptococcosis, pulmonary nonresolving, 1516
  - radiology of, 1487
- Culture, for pneumonia diagnosis atypical, 1356-1358
  - blood, 1386, 1449-1450
  - sputum, 1386-1387
- Cystic fibrosis
  - pneumonia risk in, 1342
  - Pseudomonas aeruginosa* infections in, 39-40
- Cytochrome P-450 system
  - in antidepressant metabolism, 638-639
  - in triptan metabolism, 963-964
- Cytokines
  - in respiratory infection defense, 1338-1339, 1445
  - pyrogenic, 1142-1143
- Cytomegalovirus pneumonia, radiology of, 1472-1473
- Cytopenia, antibiotic-induced, 150, 154-155
- Dalteparin
  - for deep vein thrombosis prevention, 1103
  - postoperative bleeding due to, 1285
- Danaparoid, for heparin-induced thrombocytopenia, 1284, 1307
- Deafness, antibiotic-induced, 162, 167
- Death, sudden. *See* **Mortality**.
- Deep vein thrombosis
  - anticoagulant therapy for, perioperative recommendations for, 1112
  - postoperative
    - case study of, 1101
    - incidence of, 1102
    - prophylaxis for, **1101-1107**
- Defensins, in respiratory infection defense, 1332
- Defibrillation threshold, 344
- Defibrillators
  - implantable. *See* **Implantable cardiac defibrillators**.
  - in polymorphic ventricular tachycardia, 329-331
- Deficit syndrome, in schizophrenia, 666
- Delirium, postoperative, **1229-1239**
  - case study of, 1236-1238

**Delirium (Continued)**  
 causes of, 1234–1235  
 definition of, 1229  
 diagnosis of, 1230–1234  
 differential diagnosis of, 1197–1198  
 hallmark features of, 1231  
 incidence of, 1229  
 pathogenesis of, 1229–1230  
 prevention of, 1235–1236  
 risk factors for, 1197–1198, 1234–1235  
 treatment of, 1235–1236

**Delirium tremens**, 784, 1202

**Delusions**, in schizophrenia, 665–666

**Dementia**  
*Alzheimer's. See Alzheimer's disease.*  
 diagnosis of, 587  
 presenile, 804  
 versus attention deficit/hyperactivity disorder, 762

**Dependent personality disorder**, 823–824

**Depression**, 631–644  
 antibiotic-induced, 165  
 anxiety disorder with, 696  
 diagnosis of, 581–584, 632  
 differential diagnosis of, 633–634  
 double, 632  
 economic impact of, 581–582  
 epidemiology of, 631  
 in Alzheimer's disease, 809–810  
 in bipolar disorder, 649–650, 657  
 in elderly persons, 640  
 in pediatric patients, 639–640  
 in personality disorder, 826, 830–831  
 in pregnancy, 639  
 major  
   anatomic considerations in, 562–563  
   pathophysiology of, 562–564  
   treatment of, 563  
 medical illness with, 584, 634–635  
 neurobiology of, 632–633  
 pathophysiology of, 562–564, 632–633  
 postpartum, 639  
 primary care services for, 599–600  
 psychotherapy for, 625–626, 638  
 psychotic, in schizophrenia, 667–668  
 referrals in, 640  
 suicide risk in, 584, 635  
 syncope in, 441–442  
 treatment of, 563, 635–639  
   collaborative model of, 607–609  
   cytochrome P-450 system and, 638–639  
   in Alzheimer's disease, 809–810  
   in bipolar disorder, 657  
   quality improvement in, 592–594  
   training for, 592–593

**Desipramine**, for attention deficit/hyperactivity disorder, 766

**Desmopressin**  
 for platelet dysfunction, 1281

for postoperative bleeding, 1297

**Dextran 70**, for deep vein thrombosis prevention, 1103

**Diabetes mellitus**, 1213–1228  
 classification of, 1213–1214  
 infections in, treatment of, 119  
 postoperative management of  
   case studies of, 1217–1224  
   complications in, 1216–1217  
   glycemic control in, 1214–1216  
   in emergency coronary artery bypass graft surgery, 1221–1224  
   newly diagnosed type 2, 1219–1221  
   with ketoacidosis, 1217–1219

**Diagnostic and Statistical Manual of Mental Disorders**, 581

**Diagnostic Interview Schedule**, for psychiatric disorder screening, 601

**Dialysis**, in postoperative kidney dysfunction, 1250

**Diarrhea**  
 antibiotic-induced, 170–172  
 in nutritional support, 1259

**Diary**, headache  
 for behavioral treatment, 1057–1058  
 for migraine triggers, 936

**Diazepam**  
 for alcohol withdrawal, 1205  
 for generalized anxiety disorder, 705

**Dicloxacillin**  
 for osteomyelitis, 117  
 for skin infections, 118

**Diet**  
 for migraine treatment, 1080–1081  
 migraine triggers in, 906, 912, 923–928, 1080–1081  
 in pediatric patients, 1049

**Digitalis**  
 for atrial fibrillation, 230  
 proarrhythmia due to, 511–512, 518

**Digoxin**  
 for atrial fibrillation, 1177  
 for congestive heart failure, 1164  
 for supraventricular tachycardia, 215–216  
 for ventricular tachycardia, 272  
 long-term use of, perioperative recommendations for, 1120  
 toxicity of, fascicular tachycardia in, 296

**Dihydroergotamine**  
 for cluster headache, 982–983  
 for migraine  
   in pediatric patients, 1043, 1045–1046  
   menstrual, 1021–1023

**Dilated cardiomyopathy**  
 pacemaker in, 373  
 ventricular tachycardia in, 311–312, 495–496

**Diltiazem**  
 for atrial fibrillation, 230

for supraventricular tachycardia, 214

Diphenhydramine, for migraine, 982

Disability, in headache, assessment of, 1063

Discharge process, for community-acquired pneumonia, 1434–1436

Disopyramide

- cardiac arrest due to, 510–511
- for atrial fibrillation, 234
- for supraventricular tachycardia, 217
- ventricular proarrhythmia due to, 515

Disorganization, in schizophrenia, 666, 678

Dissection, arterial, headache in, 977

Disseminated intravascular coagulation

- postoperative, 1290–1295
- blood products inducing, 1294
- in cancer, 1292–1293
- in leukemia, 1293
- in liver disease, 1291, 1295
- in obstetric complications, 1292
- in sepsis, 1291
- in trauma, 1293–1294
- pathophysiology of, 1290–1291
- stroke in, 1270
- treatment of, 1294–1296

Disulfiram, for alcohol abuse, 786

Diuretics

- for ventricular tachycardia, 272
- long-term use, perioperative recommendations for, 1121

Dizziness, antibiotic-induced, 167

DNA analysis, for atypical pneumonia

- pathogen detection, 1358

Dofetilide

- for atrial fibrillation, 234
- for ventricular tachycardia, 278
- proarrhythmia monitoring and, 520

Donepezil, for Alzheimer's disease, 805–806

Dopamine, abnormalities of, in schizophrenia, 561, 671–674

Doppler studies, in syncope, 437

Doxycycline

- for pneumonia, 57–59, 65, 68, 70
- atypical, 1359
- Streptococcus pneumoniae*, 1374–1375
- for staphylococcal infections, 6
- gastrointestinal side effects of, 170
- minimal inhibitory concentration drift of, 59
- new uses for, 125–127

Driving, after syncope, 447

Drop attacks, in autonomic failure, 465

Drug(s). *See also specific drugs.*

- abuse of. *See Substance abuse.*
- autonomic failure due to, 464–465
- delirium due to, 1230
- headache due to, 859
- hemostatic defects due to, 1280–1281
- long Q-T syndrome due to, 325–327
- long-term use of, perioperative recommendations for, 1117–1128
- antidepressants, 1125
- antiepileptics, 1124–1125
- antiparkinson agents, 1125
- cardiovascular drugs, 1120–1122
- case study of, 1117–1119
- herbals, 1126–1127
- hormones, 1123–1124
- in HIV infection, 1126
- myasthenia gravis medications, 1125
- nonprescription drugs, 1126–1127
- nonsteroidal anti-inflammatory drugs, 1119–1120
- pulmonary drugs, 1122–1123
- pneumonia associated with, 1550, 1553–1554
- pulmonary infiltration due to, versus pneumonia, 1524–1525
- Drug fever, antibiotic-induced, 153, 156–158
- Drug rash, 157–158
- Duchenne muscular dystrophy, ventricular tachycardia in, 298
- Dyslipidemia, drugs for, long-term use of, perioperative recommendations for, 1122
- Dysphagia, antibiotic-induced, 167
- Dysthymia, 631–644

  - diagnosis of, 632
  - differential diagnosis of, 633–634
  - epidemiology of, 631
  - in special patient populations, 639–640
  - medical illness with, 634–635
  - neurobiology of, 632–633
  - referral in, 640
  - suicide risk in, 635
  - treatment of, 635–639

Ear, antibiotic toxicity to, 162, 167

Eating disorders, psychotherapy for, 626

Eaton agents, 1350

Echocardiography

  - in atrial fibrillation, after cardioversion, 232–233
  - in syncope, 429–430

Ecthyma, treatment of, 119

Ehrlichiosis, treatment of, 127

Elderly persons

  - alcohol abuse in, diagnosis of, 589–590
  - antibiotic therapy for, 133–147
  - antifungal, 144
  - antituberculous agents, 141
  - antiviral, 144
  - beta-lactamase inhibitors, 138–139
  - beta-lactams, 136–138
  - cost efficiency of, 135
  - empiric, 142–144
  - fluoroquinolones, 139–140
  - macrolides, 139

Elderly persons (*Continued*)  
 pharmacokinetics and pharmacodynamics of, 134-135  
 principles of, 135  
 trimethoprim-sulfamethoxazole, 140  
 unique considerations in, 133-135  
 cardiac arrhythmias in, 527-550  
 bradycardia, 532-535  
 conduction abnormalities, 532-535  
 supraventricular, 527-532  
 ventricular, 535-544  
 dementia in, diagnosis of, 587  
 depression in, 583-584, 640  
 headache in, diagnostic testing for, 878-882  
 pneumonia in, 1441-1459  
 clinical features of, 1446  
 community-acquired  
   epidemiology of, 1442  
   prevention of, 1453-1454  
 diagnosis of, 1448-1450  
 epidemiology of, 1441-1443  
 host factors in, 1511-1512  
 long-term care facility-acquired, epidemiology of, 1442  
 mortality in, 1450-1451  
 nosocomial  
   epidemiology of, 1442-1443  
   prevention of, 1454-1455  
 pathogens causing, 1447-1450  
 predisposing factors to, 1443-1446  
 prevention of, 1453-1455  
 prognosis for, 1450-1451  
 treatment of, 1451-1452  
 syncope in, 450  
 Electrical cardioversion, for atrial fibrillation, 1177  
*Electrocardiography. See also specific arrhythmias.*  
 in supraventricular tachycardia, 210-213  
 in syncope, 429-435  
   Holter monitoring, 430-431  
   insertable loop recorders for, 433-434  
   signal-averaged, 434-435  
   transtelephonic, 431-433  
 in ventricular tachycardia  
   in elderly persons, 539-540  
   in ischemic heart disease, 270-271  
 in wide QRS complex tachycardia, 252-261  
*Electroconvulsive therapy*, for depression, 638  
*Electroencephalography*  
   in headache, 868  
   in syncope, 436-437  
 Electrolytes, in alcohol withdrawal, 1204-1205  
 Electromagnetic interference, with pacemakers, 406-411  
*Electromyography*, with feedback, for headache treatment, 1063-1065  
*Electrophysiology studies*  
   in proarrhythmia, 504-505, 514-515  
   in syncope, 435-436  
*Eletroptitan*  
   for migraine, 962  
   in pediatric patients, 1045  
   safety of, 963-964  
   structure of, 955  
*Embolism*  
   amniotic fluid, disseminated intravascular coagulation in, 1292  
   fat, postoperative stroke in, 1265  
   pulmonary, postoperative, prophylaxis for, 1101-1107  
*Emergency department, headache evaluation and management in, 971-985*  
   approach to, 971-975  
   primary, 981-983  
   secondary, 975-981  
 Employment, supported, in schizophrenia, 623-624  
*Enalapril*, for syncope, 448  
*Enalaprilat*, for hypertension, 1154  
*Encainide*  
   for ventricular tachycardia, 276  
   mortality due to, 516  
   torsades de pointes due to, 507  
   ventricular proarrhythmia due to, 514, 515, 518  
*Encephalitis*, headache in, 979  
*Encephalopathy*  
   antibiotic-induced, 160, 164  
   Wernicke's, in alcoholism, 785  
*Endarterectomy*, carotid, postoperative stroke in, 1267-1269, 1271  
*Endocarditis*  
   stroke in, 1264-1265  
   treatment of, in elderly persons, 143  
*Endotracheal aspirate*, for pneumonia diagnosis, ventilator-associated, 1574-1576  
*Endotracheal intubation*, nosocomial pneumonia risk in, 1554-1555  
*Enkephalin*, deficiency of, in migraine, 950  
*Enoxaparin*  
   for deep vein thrombosis prevention, 1102-1104  
   postoperative bleeding due to, 1285  
*Enteral feeding*, nosocomial pneumonia risk in, 1556  
*Enterobacter* pneumonia, nosocomial, 1585  
*Enterocutaneous fistula*, nutritional support in, 1261  
*Environmental factors*  
   in migraine, 912, 920-923  
   in schizophrenia, 668-669  
*Eosinophilia*, antibiotic-induced, 155  
*Eosinophilic pneumonia*, 1522  
*Epithelial cells*, in respiratory infection defense, 1332-1333

Epsilon-aminocaproic acid, for postoperative bleeding, 1287, 1289–1290

Eptifibatide, postoperative bleeding due to, 1282

Ergot compounds, for migraine, mechanism of action of, 953–954

Ergotamine for cluster headache, 999 for menstrual migraine, 1023

Erysipelas, treatment of, 118

Erythema multiforme, antibiotic-induced, 159

Erythromycin for *Campylobacter* gastroenteritis, 122 for pneumonia, 69, 1359 for staphylococcal infections, 6 for *Streptococcus pneumoniae* pneumonia, 1368–1370, 1373 hepatotoxicity of, 173 resistance to, 3, 11, 1368–1370, 1373

*Escherichia coli* infections diarrhea, 122 pneumonia nosocomial, 1585 radiology of, 1467

Esmolol, for hypertension, 1154

Estrogens for Alzheimer's disease, 807–808 for postoperative bleeding, in kidney failure, 1297 long-term use of, perioperative recommendations for, 1123–1124 migraine related to. *See* Migraine, hormone-related.

Ethambutol, blindness due to, 162

Ethanol, intravenous, for alcohol withdrawal, 1207

Etilerfrine, for syncope, 448

European Respiratory Society, pneumonia practice guidelines of, 1496

Exercise, for headache, 1082

Exercise capacity, in postoperative pulmonary risk prediction, 1135

Exercise testing, in syncope, 430

Exertional headache, **1085–1092** case studies of, 1087–1090 classification of, 1085–1087

Exposure therapy for obsessive-compulsive disorder, 614, 741 for social anxiety disorder, 724, 726–727

Eye antibiotic-induced blindness in, 162, 167 pain in, 980–981

Factor VII, recombinant, disseminated intravascular coagulation due to, 1294

Factor VIIa, for acquired factor VIII inhibitors, 1302

Factor VIII deficiency, postoperative stroke in, 1270

Familial hemiplegic migraine, 907–908, 912

Family psychotherapy, 620–621

Fasting, as migraine trigger, 920

Fat embolism, postoperative stroke in, 1265

Fatigue, in atrial fibrillation, 229

Fear, in social anxiety disorder, 712–713

Fenoldopam, for hypertension, 1154

Fetus, retained dead, disseminated intravascular coagulation in, 1292

Fever antibiotic-induced, 153, 156–158 postoperative, **1141–1149** causes of, 1141–1142, 1144–1146 clinical correlation in, 1144–1146 in infections, 1143–1144 cytokines in, 1142–1143 diagnosis of, 1146–1148 host defense mechanisms in, 1143–1144 treatment of, 1146–1148 in systemic inflammatory response syndrome, 1143

Feverfew, for headache, 1081

Fibric acid derivatives, long-term use of, perioperative recommendations for, 1122

Fibrillation, atrial. *See* Atrial fibrillation and atrial flutter.

Fibrinolysis, primary, postoperative bleeding in, 1295, 1297

Fistula, enterocutaneous, nutritional support in, 1261

Flavonoids, in wine, as migraine triggers, 925–926

Flecainide for supraventricular tachycardia, 214–217 for ventricular tachycardia, 276 mortality due to, 516 ventricular proarrhythmia due to, 515

Fluconazole, for elderly persons, 144

Flunarizine, for migraine, in pediatric patients, 1051

Flunitrazepam, 792–794

Fluoroquinolones for *Campylobacter* gastroenteritis, 122 for cholera, 122 for elderly persons, 139–140 for pneumonia community-acquired, 1504–1505 nosocomial, 105 *Streptococcus pneumoniae*, 1368, 1374–1376

for *Staphylococcus aureus* infections, 7 resistance to

Fluoroquinolones (Continued)  
*Pseudomonas aeruginosa*, 23  
*staphylococci*, 11  
*Streptococcus pneumoniae*, 59

Fluoxetine  
 for depression, 636  
 for social anxiety disorder, 722

Fluvoxamine  
 for depression, 636  
 for social anxiety disorder, 721

Folliculitis, treatment of, 118

Foramen ovale, patent, postoperative stroke in, 1265

Fortification spectra, in migraine, 945

Fosphenytoin, in cranial neuralgia, 983

Fractional excretion of sodium or chloride, in postoperative kidney dysfunction, 1246–1247

Fractures  
 disseminated intravascular coagulation in, 1293  
 fat embolism in, stroke in, 1265

Fresh-frozen plasma, for postoperative bleeding, 1288

Frovatriptan  
 for migraine, 962, 963  
 structure of, 955

Fungal infections  
 pneumonia  
 nonresolving, 1515–1516  
 radiology of, 1481–1488  
 treatment of, in elderly persons, 144

Furosemide, for hypertension, 1154

Furunculosis, treatment of, 118

*Fusobacterium nucleatum* pneumonia, nosocomial, 1585

Gabapentin, for migraine, 1051

Galantamine, for Alzheimer's disease, 805–806

Gamma-aminobutyric acid, abnormalities of  
 in anxiety disorders, 560, 566, 698  
 in schizophrenia, 670

Gamma hydroxybutyrate abuse, 792–794

Ganglionectomy, cervicothoracic, in long Q-T syndrome, 336

Gastrointestinal disorders  
 antibiotic-induced, 170–172  
 antibiotics for, 120–123  
 in migraine, 944, 947

Gatifloxacin, for pneumonia, 70, 1504

Gemfibrozil, long-term use of, perioperative recommendations for, 1122

Gender differences, in headache, 853

Generalized anxiety disorder. *See* Anxiety disorders, generalized.

Genetic factors  
 in bipolar disorder, 645–646  
 in obsessive-compulsive disorder, 740–741  
 in psychiatric disorders, 571  
 in schizophrenia, 560, 669  
 in social anxiety disorder, 718  
 in Tourette syndrome, 747–748

Gentamicin, resistance to, 10

Giant cell (temporal) arteritis, headache in, 879–882, 980, 1087–1088

Ginger, for headache, 1081

Ginkgo biloba  
 for Alzheimer's disease, 807  
 for headache, 1081

Glaucoma, headache in, 980–981

Glossitis, antibiotic-induced, 179

Glutamate, abnormalities of  
 in anxiety disorders, 566  
 in schizophrenia, 674

Glycopeptides  
 in *Staphylococcus aureus* infections, 7  
 resistance to, 3–5

Gonadal dysfunction, antibiotic-induced, 175, 178

Gonadotropin releasing hormone analogs, for menstrual migraine, 1024

Gram-negative pneumonia, community-acquired, severe, 1414

Gram stain, sputum, for pneumonia diagnosis, 1384–1386

Group psychotherapy, 620–621

Guanfacine  
 for attention deficit/hyperactivity disorder, 767  
 for Tourette syndrome, 749

Guarana, for headache, 1081

*Haemophilus influenzae* pneumonia, 43–45  
 community-acquired, severe, 1414  
 in elderly persons, 1447, 1451–1452  
 nosocomial, 1547–1548, 1584–1585  
 radiology of, 1466–1467  
 treatment of  
 bacteriostatic versus bactericidal, 57–58  
 empiric, 52–53, 55–56  
 in elderly persons, 1451–1452  
 minimal inhibitory concentration drift in, 59–60  
 monotherapy versus combination therapy in, 65–66  
 resistance potential in, 57

Hair loss, antibiotic-induced, 179

Hallucinations  
 in alcoholism, 1201  
 in schizophrenia, 665–666

Haloperidol  
 for Alzheimer's disease, 811–812

for delirium, 1236  
for Tourette syndrome, 749

Hangover headache, 925

Head injury, headache in, 978. *See also* Posttraumatic headache.

Headache  
acuity analysis of, 850–851  
acute, 1085–1086  
diagnostic testing for, 875–878  
differential diagnosis of, 873–875  
after lumbar puncture, 868, 980  
aggravating factors for, 854–855  
antibiotic-induced, 164  
caffeine-withdrawal, 924–925  
cervicogenic, 988–989  
chronic daily, 856–857  
analgesic misuse in, 1058–1059, 1067–1068  
in pediatric patients, 1039–1042  
psychiatric disorders with, 1061–1062  
relaxation treatment in, 1064–1065  
stress causing, 1060  
classification of, 849–852. *See also* International Headache Society.  
clinical evaluation of, 847–863  
clinical features of  
cluster, 998–999  
hemicrania continua, 1005  
in SUNCT syndrome, 1006–1008  
paroxysmal hemicrania, 1002–1003  
posttraumatic, 988–989  
cluster. *See* Cluster headache.  
cough, 1085–1086  
description of, 853–854  
diagnosis of, 865–885  
acute, 873–878  
arteriography in, 878  
blood tests in, 868–869  
cerebrospinal fluid examination in, 876–877  
computed tomography in. *See* Computed tomography, in headache.  
electroencephalography in, 868  
formulation of, 862  
in arteriovenous malformations, 872–873  
in emergency department, 971–985  
in older persons, 878–882  
in pediatric patients, 1046–1048  
in pregnancy, 867–868  
indications for, 865–866  
lumbar puncture in, 868, 876  
magnetic resonance imaging in, 866–867, 870–872, 875–876, 878  
migraine, 871–873, 902–903  
with normal neurologic examination, 869–871, 973–974  
differential diagnosis of  
acute, 873–875  
in older persons, 878–879

migraine, 901–906  
posttraumatic, 991–992  
epidemiology of, 887–895  
cluster, 997  
hemicrania continua, 1004–1005  
in pediatric patients, 1037–1038  
migraine, 888–890, 1019–1020  
paroxysmal hemicrania, 1002  
posttraumatic, 988  
tension-type, 890  
exertional, 1085–1092  
frequency of, 855–856, 1057–1058  
gender differences in, 853  
hangover, 925  
hemicrania as. *See* Hemicrania(s).  
history of, 858–860  
hormone-related. *See* Migraine, hormone-related.  
hot dog, 930  
impact of, 890–892  
in pediatric patients, 1037–1053  
in SUNCT syndrome, 1006–1008, 1010  
migraine. *See* Migraine.  
neuralgic, 983  
neurologic examination in, 861–862, 973–974  
pain localization in, 848–849, 854  
pathogenesis and pathophysiology of  
menstrual, 1020–1021  
migraine, 912–915, 948–953, 1020–1021  
posttraumatic, 989–991  
patient factors in, 853  
patterns of, recognition of, 849  
physical examination in, 860–862  
posttraumatic, 978, 987–996  
primary. *See also* specific headaches.  
treatment of, 981–983  
types of, 972  
versus secondary, 850  
rebound, 1040  
red flags in, 972  
relieving factors for, 855  
secondary  
in older persons, 879  
treatment of, 975–981  
types of, 973  
versus primary, 850  
serious/severe, 902  
diagnostic testing for, 875–878  
differential diagnosis of, 873–875  
recognition of, 851–852  
sexual activity-induced, 1085–1086  
sick, 951  
sneeze-induced, 1085–1086  
subacute, 851, 856  
symptom analysis of, 852–858  
temporal sequence of, 855–856  
tension-type. *See* Tension-type headache.  
thunderclap, 976, 1086–1087  
treatment of. *See also* Migraine, treatment of.

Headache (Continued)

- acupuncture in, 1078–1079
- alternative, **1077–1084**
- behavioral, **1055–1075**
- cluster, 999–1000
- hemigrana continua, 1005–1006
- herbal, 1081–1082
- hypnic, 1009–1011
- impact of, 890–892
- in emergency department, **971–985**
- in pediatric patients, 1042–1046
- in SUNCT syndrome, 1008
- in trigeminal neuralgia, 983
- menstrual migraine, 1021–1025
- mind-body techniques in, 1079–1080
- multidisciplinary, 1068
- nutritional, 1080–1081
- paroxysmal hemigrana, 1003–1004
- physical approaches to, 1082
- posttraumatic, 992–994, 1065
- primary, 981–983
- secondary, 975–981
- tension-type, 982, 1065–1067
- versus other head pains, 848

Health Insurance Experiment, for primary care of psychiatric disorders, 600

Heart

- disease of, headache in, 1088–1089
- transplantation of, pacemaker in, 373

Heart block

- antibiotic-induced, 169
- in elderly persons, 533–534
- pacemaker in, 370, 390–400
- perioperative, 1181–1182

Heart failure

- congestive
- pacemaker in, 382–386
- perioperative, 1161–1166
- ventricular tachycardia in, treatment of, 281–282

Heart rate, in wide QRS complex tachycardia, 253

Heat therapy, for headache, 1082

*Helicobacter pylori* infections, treatment of, 120–121

Hematologic disorders, antibiotic-induced, 150–155

Hematuria, in postoperative kidney dysfunction, 1246

Hemigrana(s)

- alternating, in migraine, 901
- paroxysmal, 1000–1004, 1010

Hemigrana continua, 1004–1006, 1010

Hemiplegia, in familial hemiplegic migraine, 907–908, 912

Hemophilia, postoperative stroke in, 1270

Hemorrhage. *See also* Bleeding

- alveolar, in systemic lupus erythematosus, versus pneumonia, 1423
- subarachnoid. *See* Subarachnoid hemorrhage.

Hemostasis, physiology of, 1277–1280

Heparin

- anesthesia and, 1113–1114
- for deep vein thrombosis prevention, 1102–1104
- for disseminated intravascular coagulation, 1295
- for myocardial infarction, 1160
- perioperative, 1114–1115
- bleeding risks and, 1282–1286, 1302–1307
- thrombocytopenia due to, 1283–1284, 1305–1307
- pharmacokinetics of, 1112–1113
- reversal of, in postoperative stroke, 1273

Hepatitis, antibiotic-induced, 171, 174

Herbal remedies

- for headache, 1081–1082
- perioperative recommendations for, 1126–1127

Heroin abuse, 787–789

Hip, arthroplasty of, thrombosis prophylaxis after, **1101–1107**

Hippocampus, pathology of, in schizophrenia, 672–673

Hirudin, for heparin-induced thrombocytopenia, 1284, 1306–1307

His-Purkinje reentry circuits, ventricular tachycardia in, 284–286

Histamine, as migraine trigger, 925–926

Histoplasmosis, pulmonary nonresolving, 1515

radiology of, 1481–1482

Histrionic personality disorder, 824–825

HIV infection. *See* Human immunodeficiency virus infection.

Hodgkin's disease, pulmonary, versus pneumonia, 1520–1522

Holter monitoring

- in supraventricular tachycardia, 212
- in syncope, 430–431

Homeopathy, for headache, 1081–1082

Hormones

- long-term use of, perioperative recommendations for, 1123–1124
- migraine related to. *See* Migraine, hormone-related.

Horner's syndrome, in cluster headache, 998–999

Hospital-acquired pneumonia. *See* Pneumonia, nosocomial.

Host defense, in pneumonia, **1329–1347**

- adaptive immunity, 1335–1340, 1343
- defects in, 1340–1343
- epithelial cells, 1332–1333
- humoral immunity, 1331–1332, 1339–1340, 1445–1446
- innate immunity, 1331–1335, 1340, 1342
- noncellular antimicrobial components, 1331–1332, 1342

nonspecific, 1330–1331  
phagocytosis, 1333–1335

Host factors, in pneumonia  
nonresolving, 1511–1513  
nosocomial, 1551–1552

Hot dog headache, 930

Human immunodeficiency virus infection  
drugs for, perioperative recommendations for, 1126  
*Pneumocystis carinii* pneumonia in, 1517  
pneumonia risk in, 1341, 1434  
postoperative stroke in, 1270  
tuberculosis in, 1480

Humoral immunity, in respiratory infection defense, 1331–1332, 1339–1340, 1445–1446

Hydralazine, for congestive heart failure, 1164

Hydrocortisone, for surgical stress, 1315

Hydroxyzine, for generalized anxiety disorder, 706

Hyperactivity, in ADHD. *See* Attention deficit/hyperactivity disorder.

Hyperalimentation. *See* Nutritional support.

Hyperbilirubinemia, antibiotic-induced, 174

Hypercoagulability  
anticoagulant therapy for, perioperative recommendations for, 1112  
postoperative stroke in, 1265–1267

Hyperglycemia, in nutritional support, 1258–1259

Hyperkalemia, in postoperative kidney dysfunction, 1248

Hypernatremia, in postoperative kidney dysfunction, 1247

Hyperphosphatemia, in postoperative kidney dysfunction, 1248–1249

Hyperpigmentation, antibiotic-induced, 179

Hypersensitivity reactions, antibiotic-induced, 153, 156–160

Hypertension  
antibiotic-induced, 169  
intracranial, headache in, 979–980  
perioperative, 1151–1154

Hypertrophic cardiomyopathy  
pacemaker in, 379–382  
ventricular tachycardia in, 286–288, 310–311

Hyperuricemia, in postoperative kidney dysfunction, 1249

Hypnic headache syndrome, 1009–1011

Hypoalbuminemia, in postoperative kidney dysfunction, 1249

Hypocalcemia, in postoperative kidney dysfunction, 1249

Hypoglycemia, as migraine trigger, 920

Hypokalemia  
in congestive heart failure, 1164  
in postoperative kidney dysfunction, 1248

Hypomania, in bipolar disorder, 653

Hyponatremia  
in postoperative kidney dysfunction, 1247  
in schizophrenia, 679

Hypotension  
antibiotic-induced, 163, 169  
kidney dysfunction in, 1242, 1244  
orthostatic. *See* Syncope, in autonomic dysfunction.

perioperative, 1153, 1155  
myocardial ischemia in, 1155  
stroke in, 1264

Hypothalamic-pituitary-adrenal axis dysfunction of  
in anxiety disorders, 566–567, 570, 699  
in depression, 563–564  
physiology of, 1312  
suppression of, 1313–1314  
case study of, 1313–1314  
testing of, 1314–1315  
treatment of, 1314–1315  
surgical stress effects on, 1312–1313

Hypovolemia, in trauma, disseminated intravascular coagulation in, 1293–1294

Hypoxemia index, in pneumonia, 1421

Hysterectomy, in menstrual migraine, 1024, 1027

Ibuprofen, for headache, in pediatric patients, 1042–1043

Ibutilide  
for atrial fibrillation, 233, 1177  
for supraventricular tachycardia, 214–215

Imipenem  
for elderly persons, 138  
for nosocomial pneumonia, 101–102  
for *Pseudomonas aeruginosa* infections, 29–33  
pharmacokinetics of, 24  
resistance to, 21–22, 30–31  
neurologic side effects of, 161

Imipramine  
for generalized anxiety disorder, 705  
for social anxiety disorder, 723

Immune system, in respiratory infection defense  
adaptive, 1335–1340, 1343  
humoral, 1331–1332, 1339–1340, 1445–1446  
innate, 1331–1335, 1340, 1342

Immunization. *See* Vaccines.

Immunoabsorption column, for acquired factor VIII inhibitors, 1302

Immunodeficiency, pneumonia risk in, 1341–1343

Immunoglobulin(s), in respiratory infection defense, 1331–1332, 1339–1340

Impetigo, treatment of, 118

Implantable cardiac defibrillators, 343–367

- complications of, 357–361
- components of, 349–351
- defibrillation mechanisms in, 344–346
- electromagnetic interference with, 410–411
- follow-up for, 355–357
- for atrial fibrillation, 236, 238–239
- for bradycardia, 350–351
- for long Q-T syndrome, 337
- for primary prevention, 362–363
- for ventricular tachycardia

  - in coronary artery disease, 314–315
  - in elderly persons, 543–544
  - in hypertrophic cardiomyopathy, 288, 311
  - in ischemic heart disease, 272, 274–275, 279, 281–283

historical perspective of, 343–344

implantation technique for, 351–355

indications for, 360, 362–363

pacemaker interactions with, 352

perioperative management of, 1183

sensing in, 346–349

Impulsivity, in attention deficit/ hyperactivity disorder, 759

Inattention, in attention deficit/ hyperactivity disorder, 759–760

Indinavir, metabolic side effects of, 175, 177

Indomethecin

- for hemicrania continua, 1005–1006
- for paroxysmal hemicrania, 1003–1004

Infection(s), of implantable cardiac defibrillator pocket, 357–358

Infection control

- for nosocomial pneumonia, 1552–1553
- for *Staphylococcus aureus* infections, antibiotic-resistant, 5

Infectious Diseases Society of America, pneumonia practice guidelines of, 1496–1499

Inflammation

- as pneumonia bacterial defense, 1446
- neurogenic, in migraine, 949–950

Influenza

- pneumonia in

  - chemoprophylaxis for, 1454, 1539–1541
  - epidemiology of, 1535–1536
  - nonresolving, 1516
  - nosocomial, 1586
  - radiology of, 1471–1472
  - vaccines for, 1454, 1535–1541

- treatment of, in elderly persons, 144

Information processing, in obsessive-compulsive disorder, 740

Injury, brain, headache after. *See* Posttraumatic headache

Innate immunity, in respiratory infection defense, 1331–1335, 1340, 1342

Insulin

- for diabetes mellitus, postoperative, 1214–1224

perioperative recommendations for, 1125

Interferons, in respiratory infection defense, 1338–1339, 1445

Interleukin(s)

- in respiratory infection defense, 1338, 1445
- pyrogenic, 1142–1143

International Headache Society, headache classification of, 849–850

- cluster, 998
- exertional, 1085–1087
- migraine, 899–900
- pediatric migraine, 1038–1039
- posttraumatic, 987
- tension-type, 904

Interpersonal psychotherapy, 620

Interstitial nephritis, antibiotic-induced, 175–176

Intracardiac mapping, in atrial fibrillation, 237

Intracranial hypertension, headache in, 979–980

Intubation, nosocomial pneumonia risk in, 1340–1341, 1554–1555

Ischemia, renal, postoperative, 1243

Ischemic heart disease, ventricular tachycardia in, 270–283, 332–333

Isepamicin, for *Pseudomonas aeruginosa* infections, 37–38

Isoniazid

- for elderly persons, 151
- hepatitis due to, 171
- neurologic side effects of, 161

Isoproterenol, for polymorphic ventricular tachycardia, 331

Job's syndrome, pneumonia risk in, 1341

Junctional reciprocating tachycardia, 199, 202

Junctional tachycardia, 206

Kartagener's syndrome, pneumonia risk in, 1340

Ketoacidosis, diabetic, postoperative management in, 1217–1219

Ketorolac, for migraine, 982

Kidney dysfunction

- antibiotic-induced, 173, 175–176

in diabetes mellitus, postoperative considerations in, 1216-1217

postoperative, 1241-1254  
assessment of, 1246-1249  
causes of, 1242-1244  
detection of, 1245-1246  
epidemiology of, 1241  
mortality in, 1241  
prevention of, 1244  
treatment of, 1249-1250

postoperative bleeding in, 1297

Kindling, in alcohol withdrawal, 783

*Klebsiella pneumoniae* pneumonia  
nosocomial, 84-85, 98, 1585  
radiology of, 1463-1464  
treatment of, in elderly persons, 1452

Knee, arthroplasty of, thrombosis  
prophylaxis after, 1101-1107

Korsakoff's amnestic disorder, in  
alcoholism, 785

LAAM (*l*-acetyl-*a*-methadol), for opioid  
abuse, 789

Labetalol, for hypertension, 1154

Lactate, sensitivity to, in anxiety disorders, 567

Lange-Jervell-Nielsen syndrome, long Q-T  
interval in, 334

Lawrence risk index, for postoperative  
pulmonary complications, 1134-1135

Learning disorders, versus attention  
deficit/hyperactivity disorder, 762

Left ventricular tachycardia, idiopathic,  
289-291

*Legionella* pneumonia, 46-47  
community-acquired, 1349  
clinical features of, 1351  
coinfection with, 1354-1356  
diagnosis of, 1357-1358, 1387  
epidemiology of, 1351-1354  
prognosis for, 1358-1359  
severe, 1413  
treatment of, 1358-1359

differential diagnosis of, 48-49  
nonresolving, 1514

nosocomial, 94, 1548, 1586  
radiology of, 1464-1465  
treatment of, 1358-1359, 1502-1503  
empiric, 51-53  
monotherapy versus combination ther-  
apy in, 63

Lepirudin, for heparin-induced  
thrombocytopenia, 1306-1307

Leukemia, disseminated intravascular  
coagulation in, 1293

Leukopenia, antibiotic-induced, 150

Levofloxacin  
for pneumonia

community-acquired, 65-66, 68, 70,  
1504

nosocomial, 102, 105

for staphylococcal infections, 6

minimal inhibitory concentration drift  
of, 59

Levothyroxine, long-term use of,  
perioperative recommendations for,  
1125

Lewy bodies, dementia with, 804, 813

Lidocaine  
for polymorphic ventricular tachycardia,  
331

for wide QRS complex tachycardia, 263

Liebowitz Social Anxiety Scale, in social  
anxiety disorder, 714-715, 717

Light, as migraine trigger, 920-921

Lightheadedness, in atrial fibrillation, 229

Linezolid, for staphylococcal infections, 6,  
12

Lipid pneumonia, 1525-1526

Lithium  
for bipolar disorder, 655, 657-658  
for cluster headache, 999  
for hypnic headache syndrome, 1009  
long-term use of, perioperative recom-  
mendations for, 1126

Liver disorders  
antibiotic-induced, 171, 173-174  
disseminated intravascular coagulation  
in, 1291, 1295  
in nutritional support, 1260-1261

Long Q-T syndrome  
acquired, 325-327  
evaluation of, 332  
treatment of, 329-332

cellular mechanisms of, 327-329

congenital, 334-337

definition of, 323

pacemaker in, 377-379

ventricular tachycardia in, 291-294

Lorazepam, for alcohol withdrawal, 1205

Loxapine, for Alzheimer's disease, 811

Lumbar puncture  
headache after, 868, 980  
in headache diagnosis, 868, 876

Lung  
antibiotic-induced reactions in, 162-163,  
168

biopsy of, in pneumonia, 1391

cancer of, versus pneumonia, 1520-1522

dysfunction of, in elderly persons, 1445

infections of. *See* Pneumonia.

injury of, pneumonia risk in, 1341

occupational diseases of, versus pneumo-  
nia, 1527

Lupus pneumonitis, versus pneumonia,  
1523

Lyme disease, treatment of, 127

Lymphadenopathy, antibiotic-induced, 179

Lymphoma, pulmonary, versus pneumonia, 1520–1522

Macrolides. *See also specific drugs.*  
for elderly persons, 139  
for pneumonia, community-acquired, 1505

Macrophages, in respiratory infection defense, 1333–1335, 1445

Magnesium  
for migraine, 1080–1081  
for polymorphic ventricular tachycardia, 331  
for wide QRS complex tachycardia, 264

Magnetic resonance angiography, in headache, 878

Magnetic resonance imaging  
in anxiety disorders, 567–568, 700  
in headache, 866–867, 870–872, 875–876, 878

Malnutrition, pneumonia in, 1444–1445

Manic-depressive illness. *See* Bipolar disorder.

Mapping, intracardiac, in atrial fibrillation, 237

Marital psychotherapy, 620–621

Massage, for headache, 1082

Maximal oxygen uptake, in postoperative pulmonary risk prediction, 1135

Maze procedure, in atrial fibrillation, 235–236

MDMA (3,4-methylenedioxymethamphetamine) abuse, 792–794

Mechanical ventilation, pneumonia in. *See* Pneumonia, ventilator-associated.

Meclobemide, for social anxiety disorder, 722–723

Medical Outcomes Study, for primary care of psychiatric disorders, 600

Meningitis  
aseptic, antibiotic-induced, 164  
headache in, 979  
treatment of, in elderly persons, 143

Menopause, migraine related to, 1025–1028

Menstrual migraine, 906, 1018–1025  
definitions of, 1019–1020  
endocrinology of, 1018–1019  
epidemiology of, 1019–1020  
pathogenesis of, 1020–1021  
treatment of, 1021–1025

Meropenem  
for elderly persons, 138  
for pneumonia  
community-acquired, 66  
nosocomial, 101–102, 104  
for *Pseudomonas aeruginosa* infections, 29–33

pharmacokinetics of, 24  
resistance to, 21–22, 30–32

Metabolic disorders, antibiotic-induced, 175, 177–178

Methadone, for opioid abuse, 788–789

Methicillin, resistance to, staphylococci, 3–5, 6–7, 10, 127

Methimazole, long-term use of, perioperative recommendations for, 1125

Methyldopa, for hypertension, 1154

3,4-Methylenedioxymethamphetamine abuse, 792–794

Methylphenidate  
for attention deficit/hyperactivity disorder, 767  
for syncope, 470

Methysergide  
for cluster headache, 999–1000  
for migraine, 956

Metoclopramide  
for cluster headache, 982  
for migraine, 982, 1045–1046

Metoprolol  
for supraventricular tachycardia, 214–217  
for ventricular tachycardia, 275

Metronidazole  
for abdominal infections, 121  
for diabetic ulcers, 119  
for elderly persons, 141  
for *Helicobacter pylori* infections, 120  
new uses for, 129–130

Mexiletine, ventricular proarrhythmia due to, 514, 518

Michigan Alcoholism Screening Test, 1195

Midodrine, for syncope, 448, 470

Migraine, 943–957  
aggravating factors for, 854–855  
atypical, 907  
basilar, 907  
bipolar disorder with, 655  
chronic, 944  
classic (with aura), 898–901  
classification of, 899–900  
clinical features of, 943–948  
clinical spectrum of, 897–909  
common (without aura), 898–901, 903–906, 951  
definition of, 943  
diagnosis of  
criteria for, in pediatric patients, 1038–1040  
neuroimaging in, 871–873  
differential diagnosis of, 901–903  
epidemiology of, 888–890  
in pediatric patients, 1037–1038  
menstrual, 1019–1020  
familial hemiplegic, 907–908, 912  
genetic factors in, 912–913

hormone-related, 1017-1035  
in contraceptive use, 1028-1030  
in hormone replacement therapy, 1023-1028  
menopausal, 1025-1028  
menstrual, 906, 1018-1025  
impact of, 891-892  
in pediatric patients, 1037-1038  
diagnostic criteria for, 1038-1040  
prevention of, 1048-1051  
treatment of, 1042-1046  
incidence of, 888-889  
latency of, 901  
menstrual, 906, 1018-1025  
mimics of, 901-902  
pathogenesis of, 948-953  
menstrual, 1020-1021  
triggers and, 912-915  
pathophysiology of, 959-960  
phases of, 898, 903  
postdrome of, 903  
practice guidelines for, 873  
prevalence of, 889-890  
prevention of, 956-957, 1023-1025, 1048-1051  
prodrome of, 898  
psychiatric disorders with, 1061-1062  
refractory (status migrainosus), 907  
transformed, 944  
in pediatric patients, 1040  
versus chronic tension-type headache, 905-906  
treatment of  
abortive, 953-955  
behavioral. *See Behavioral therapy, for headache.*  
emergency, 981-982  
in pediatric patients, 1042-1046  
menstrual, 1021-1025  
preventive, 956-957, 1022-1025, 1048-1051  
triptans in. *See Triptans; specific triptans.*  
triggers of, 906-907, 911-941  
behavioral, 912, 918-920  
chemical, 912, 927-931  
clinical features of, 916-918  
clustering of, 917-918  
definition of, 911-912  
diary for, 936  
dietary, 906, 912, 923-928, 1080-1081  
environmental, 912, 920-923  
epidemiology of, 915-916  
frequency of, 917-918  
hormonal, 912, 1017-1035  
management of, 935-936  
overlap of, 917-918  
pathogenesis and, 912-915  
prioritization of, 935-936  
scientific evidence for, 932-935  
time for precipitation, 916-917  
versus arteriovenous malformations, 872-873  
versus cluster-migraine syndrome, 1008-1010  
with aura, 898-901, 945, 948  
without aura, 898-901, 951  
versus tension-type headache, 903-906  
Mind-body techniques, in headache treatment, 1079-1080  
Mini International Neuropsychiatric Interview, in social anxiety disorder, 714  
Mini-mental status examination, in delirium, 1233  
Minimal inhibitory concentration drift, in pneumonia treatment, 59-60  
Minocycline  
for coagulase-negative staphylococcal infections, 12  
for staphylococcal infections, 6  
gastrointestinal side effects of, 170  
new uses for, 125-127  
ototoxicity of, 162  
Minute ventilation sensors, for pacemakers, 401-402  
Mirtazapine, for depression, 637  
Mitral valve prolapse, ventricular tachycardia in, 307, 309-310  
Monoamine oxidase inhibitors  
for attention deficit/hyperactivity disorder, 769-770  
for depression, 637  
for social anxiety disorder, 722-723  
long-term use of, perioperative recommendations for, 1125  
triptan interactions with, 963  
Monobactams. *See also Aztreonam.*  
for elderly persons, 138  
Monomorphic ventricular tachycardia. *See Ventricular tachycardia, monomorphic.*  
Monosodium glutamate (MSG), as migraine trigger, 928-929  
Moraxella catarrhalis pneumonia, 43-45  
nosocomial, 1548  
radiology of, 1467  
treatment of  
bacteriostatic versus bactericidal, 57-58  
empiric, 52-53, 55-56  
monotherapy versus combination therapy in, 65-66  
resistance potential in, 57  
severity factors in, 56  
Morganella pneumonia, radiology of, 1464  
Moricizine  
for ventricular tachycardia, 276  
ventricular fibrillation due to, 514  
Mortality  
in atrial fibrillation, 227-228

Mortality (Continued)

- in long Q-T syndrome, 323, 334–335
- in pneumonia
  - atypical, 1358
  - community-acquired, 1382–1383
  - drug-resistant *Streptococcus pneumoniae*, 1371–1373
  - in elderly persons, 1450–1451
  - nosocomial, 1583–1584
- in syncope, 445–446
- in tachycardia, defibrillators for. *See* Implantable cardiac defibrillators.
- in torsades de pointes, short-coupled variant of, 323
- in ventricular tachycardia, 267–268, 305
- in Brugada's syndrome, 294–295, 323
- in Chagas' disease, 299
- in coronary artery disease, 312–315
- in dilated cardiomyopathy, 311–312
- in hypertrophic cardiomyopathy, 287–288, 310–311
- in ischemic heart disease, 270–283
- in mitral valve prolapse, 309–310
- in sarcoidosis, 298
- polymorphic, 333–335
- without structural heart disease, 306–307
- pacemaker effects on, 389, 391

Motion sickness, as migraine trigger, 906

Motor activity, excessive, in attention deficit/hyperactivity disorder, 759

Motor tic disorder, chronic, 742–743

Moxalactams, hematologic effects of, 152

Moxifloxacin, for pneumonia, community-acquired, 1504

Mucociliary escalator, in respiratory infection defense, 1330–1331

- defects of, 1340, 1342
- in elderly persons, 1444

Multifocal atrial tachycardia, 206, 208

perioperative, 1179–1180

Multiple system atrophy, syncope in, 462–463

Muscle relaxants, pulmonary complications due to, 1132

Muscular dystrophy, ventricular tachycardia in, 298

Myalgia, antibiotic-induced, 179

Myasthenia gravis, drugs for, perioperative recommendations for, 1125

Mycobacterial infections. *See also* Tuberculosis.

- nontuberculous
  - nonresolution of, 1515
  - radiology of, 1480–1481
- Mycobacteria pneumoniae* pneumonia, 46
- community-acquired, 1349
- clinical features of, 1351
- coinfection with, 1354–1356
- diagnosis of, 1356–1357, 1387

epidemiology of, 1352–1354

historical perspective of, 1350

prognosis for, 1358–1359

severe, 1413–1414

treatment of, 1358–1359

differential diagnosis of, 48–49

in elderly persons, 1447

nonresolving, 1514

radiology of, 1468–1469

treatment of, 1502–1503

- community-acquired, 1358–1359
- empiric, 53
- monotherapy versus combination therapy in, 63, 65–66

Myocardial ischemia and myocardial infarction

- depression and, 634–635
- pacemaker in, 371
- perioperative, 1155–1161
  - incidence of, 1156–1157
  - pathophysiology of, 1155
  - presentation of, 1156–1157
  - prevention of, 1157–1159
  - stroke in, 1264–1265
  - treatment of, 1159–1161
- ventricular tachycardia in, 270–283, 312–315
  - catheter ablation of, 493–495
  - polymorphic, 332–333
  - wide QRS complex tachycardia in, 250

Myocarditis

- acute, ventricular tachycardia in, 298
- antibiotic-induced, 169

Myotonic dystrophy, ventricular tachycardia in, 298

Nafcillin

- for osteomyelitis, 117
- for staphylococcal infections, 6–7

Nail disorders, antibiotic-induced, 179

Naltrexone

- for alcohol abuse, 786–787
- for opioid abuse, 789

Naratriptan

- for migraine, 962
  - in pediatric patients, 1044
  - menstrual, 1023
  - safety of, 963
  - structure of, 955

Narcissistic personality disorder, 827–828

Narcotics

- abuse of, 787–789
- long-term use of, perioperative recommendations for, 1126

Narrow-complex tachycardia, perioperative, 1178–1179

Nasal intubation, nosocomial pneumonia risk in, 1555

Nasogastric intubation, nosocomial pneumonia risk in, 1556

Nausea, antibiotic-induced, 170, 172

Nebulizers, nosocomial pneumonia due to, 1557

Necrosis, hepatic, antibiotic-induced, 173–174

Necrotizing pneumonia, nosocomial, 84–93

- multiple pathogens in, 89, 91
- Pseudomonas aeruginosa*, 89–93
- Staphylococcus aureus*, 85–88

Nefazodone, for depression, 636

Neoplasia. *See also* Cancer.

- lung, versus pneumonia, 1520–1522

Neostigmine, long-term use of, perioperative recommendations for, 1125

Nephropathy, diabetic, postoperative considerations in, 1216–1217

Nephrotoxicity, of antibiotics, 173, 175–176

Neuralgia, headache in, 983

Neuritic plaques, in Alzheimer's disease, 804

Neurofibrillary tangles, in Alzheimer's disease, 804

Neurogenic inflammation, in migraine, 949–950

Neuroleptic(s)

- for alcohol withdrawal, 1207
- long-term use of, perioperative recommendations for, 1126

Neuroleptic malignant syndrome, in antipsychotic agent therapy, 675

Neurologic disorders

- antibiotic-induced, 160–162, 164–167
- drugs for, long-term use of, perioperative recommendations for, 1124–1125

Neurologic examination, in headache, 861–862

Neuromuscular blockade

- antibiotic-induced, 161, 165
- nosocomial pneumonia associated with, 1553
- pulmonary complications due to, 1132

Neuropathy, diabetic, postoperative considerations in, 1216–1217

Neurotransmitters, abnormalities of, in psychiatric disorders, 571

- anxiety disorders, 565–567, 570, 698–699
- depression, 563–564, 622–623
- obsessive-compulsive disorder, 739
- schizophrenia, 561–562, 670–673
- Tourette syndrome, 746

Neutropenia

- antibiotic-induced, 150, 154
- Pseudomonas aeruginosa* infections in, 39

Niacin, long-term use of, perioperative recommendations for, 1122

Nicardipine, for hypertension, 1154

Nicotine

- dependence on, 591–592, 790–791
- in schizophrenia, 679
- for Tourette syndrome treatment, 759

Nitrates and nitrates

- as migraine triggers, 930–931
- for congestive heart failure, 1164

Nitrofurantoin

- hepatotoxicity of, 173
- pulmonary side effects of, 162–163

Nitroglycerin

- as migraine trigger, 930
- for hypertension, 1154
- for myocardial infarction, 1160

Nitroprusside

- for congestive heart failure, 1165
- for hypertension, 1154

Nocardiosis, pulmonary

- nonresolving, 1517
- radiology of, 1487–1488

Nonsteroidal anti-inflammatory drugs

- for Alzheimer's disease, 808
- for headache
- menstrual migraine, 1023
- tension-type, 982
- long-term use of, perioperative recommendations for, 1119–1120

Norepinephrine, abnormalities of, 563

- in anxiety disorders, 565, 570, 698
- in depression, 632–633

Nortriptyline, for attention deficit/hyperactivity disorder, 768

Nosocomial pneumonia. *See* Pneumonia, nosocomial.

Nursing homes, pneumonia in, epidemiology of, 1442

Nutritional support

- for alcohol abuse, 1204–1205
- for pneumonia prevention, 1444–1445
- postoperative, 1255–1262
- administration modes for, 1257
- complications of, 1258–1261
- early feeding in, 1258
- goals of, 1255
- in diabetes mellitus, 1222–1223
- in enterocutaneous fistula, 1261
- patient selection for, 1256
- solutions for, 1257–1258
- team for, 1256–1257
- preoperative, 1256

Obesity, postoperative pulmonary complications in, 1130–1131

Obsessive-compulsive disorder, 735–742

- clinical features of, 736–737
- consequences of, 736
- definition of, 585
- genetics of, 740–741
- neuroimaging in, 738
- pathophysiology of, 735, 738–741

**Obsessive-compulsive disorder (Continued)**  
 psychotherapy for, 624  
 Tourette syndrome with, 743–744  
 treatment of, 741–742  
 versus Tourette syndrome, 735, 737

**Obsessive-compulsive personality disorder**, 826–827

**Obstetric complications**, disseminated intravascular coagulation, 1292

**Odors**, as migraine triggers, 921

**Olanzapine**  
 for Alzheimer's disease, 812–813  
 for bipolar disorder, 655–656  
 for schizophrenia, 675

**Olivocerebellar atrophy**, syncope in, 463

**Opioids**  
 abuse of, 787–789  
 long-term use of, perioperative recommendations for, 1126

**Oral contraceptives**  
 long-term use of, perioperative recommendations for, 1123  
 migraine related to, 1028–1030

**Oral hypoglycemics**, perioperative, 1125, 1219–1220

**Orogastric intubation**, nosocomial pneumonia risk in, 1556

**Orthodromic atrioventricular node reentrant tachycardia**, 197, 199–200, 204

**Orthostatic hypotension**. *See* **Syncope**, in autonomic dysfunction.

**Oseltamivir**, for influenza pneumonia prophylaxis, 1539–1541

**Osteomyelitis**  
 antibiotics in, 117–118, 128  
*Pseudomonas aeruginosa*, 39

**Otototoxicity**, antibiotic-induced, 162, 167

**Ovarian cycle**, migraine related to. *See* **Menstrual migraine**.

**Ovariectomy**, in menstrual migraine, 1024, 1027

**Oxacillin**  
 for staphylococcal infections, 6–7  
 resistance to, 6, 10

**Oxazolidinones**, for *Staphylococcus aureus* infections, 8–9

**Oxygen therapy**, for cluster headache, 999

**Pacemaker syndrome**, 394

**Pacemakers**, 369–421  
 atrial  
   single-chamber, 396–397  
   versus ventricular, 389, 391–396  
 automaticity of, 404–406  
 diagnostics for, 404–406  
 dual-sensor, 404  
 electromagnetic interference with, 406–411

for atrial fibrillation, 236, 239, 386–389  
 for atrial tachyarrhythmias, 399–400  
 for bradycardia, in elderly persons, 534  
 for cardiomyopathy, 379–382  
 for congestive heart failure, 382–386  
 for long Q-T syndrome, 377–379  
 congenital, 336  
 for neurocardiogenic syncope, 374–377  
 for syncope, 449, 470  
 implantable cardiac defibrillator interaction with, 352

in implantable cardiac defibrillator, 350–351

indications for, guidelines for, 369–374  
 mode selection for, 389–400  
 perioperative management of, 1182–1183  
 rate-adaptive, 398–404  
 sensors in, 401–404  
 temporary, for polymorphic ventricular tachycardia, 331

**ventricular**  
 rate-adaptive, 398–399  
 single-lead, 397–398  
 versus atrial, 389, 391–396

**Palpitations**  
 in atrial fibrillation, 229  
 in supraventricular tachycardia, 209–210

**Pancreatitis**, antibiotic-induced, 171–172

**Panic disorder**  
 anxiety disorder with, 696  
 definition of, 585  
 psychotherapy for, 625  
 syncope in, 441–442  
 versus social anxiety disorder, 713–714

**Panipenem**, for *Pseudomonas aeruginosa* infections, 30, 33

**Paranoid personality disorder**, 832–833

**Parenteral nutrition**. *See* **Nutritional support**.

**Paresthesias**, circumoral, antibiotic-induced, 167

**Parkinson's disease**, drugs for, perioperative recommendations for, 1125

**Paroxetine**  
 for depression, 636  
 for generalized anxiety disorder, 705  
 for social anxiety disorder, 721, 726  
 for syncope, 448

**Paroxysmal hemicrania(s)**, 1000–1004, 1010

**Paroxysmal supraventricular tachycardia**, perioperative, 1178–1179

**Patent foramen ovale**, postoperative stroke in, 1265

**Patient Health Questionnaire**  
 for psychiatric disorder screening, 581  
 in depression diagnosis, 583

**Pediatric patients**  
 depression in, 639–640  
 headache in, 1037–1053

chronic daily, 1039–1042  
 laboratory tests for, 1046–1048  
 migraine, 1037–1039, 1042–1046, 1048–1051  
 treatment of, 1042–1046

Pelvic fracture, disseminated intravascular coagulation in, 1293

Pemoline, for attention deficit/hyperactivity disorder, 767–768

Penicillin(s)  
 anaphylactic reactions to, 157  
 for animal bite infections, 119–120  
 for elderly persons, 136–137  
 for pneumonia, 101  
 for *Pseudomonas aeruginosa* infections, 19–28  
 adverse effects of, 25  
 dosage for, 25  
 pharmacokinetics of, 20, 24–25  
 resistance in, 19–23  
 for skin infections, 118  
 for *Staphylococcus aureus* infections, 5–7  
 for toxic shock syndrome, 119  
 gastrointestinal side effects of, 170  
 hematologic effects of, 152  
 resistance to  
   *Pseudomonas aeruginosa*, 19–23  
   staphylococci, 2–3, 10  
   *Streptococcus pneumoniae*, 58–59, 1367–1375, 1503

Pentamidine  
 hypotension due to, 163  
 pancreatitis due to, 171

Pergolide, long-term use of, perioperative recommendations for, 1125

Peripheral neuropathy, antibiotic-induced, 161, 166

Personality disorders, 819–837  
 anxious-fearful, 821–822  
 Axis II type, 820–822  
 cold, deceitful (antisocial), 828–829  
 demanding, 823–829  
 dependent, 823–824  
 distant, 829–833  
   aloof (schizoid), 831–832  
   dramatic-emotional, 821, 824–825  
   guarded, suspicious (paranoid), 832–833  
   headache in, 1062–1063  
   idealizing, easily disappointed (borderline), 825–826  
   indifferent, pessimistic (quietly depressive), 830–831  
   long-suffering, complaining (manifestly depressive), 826  
   odd (schizotypal), 832  
   odd-eccentric, 821  
   orderly, controlled (obsessive-compulsive), 826–827  
   subjective-descriptive nosology for, 822  
   superior, critical (narcissistic), 827–828

timid, apprehensive (avoidant), 830  
 versus social anxiety disorder, 714

Phagocytosis, in respiratory infection defense, 1333–1335

Phenelzine, for social anxiety disorder, 722–723

Phenobarbital, for alcohol withdrawal, 1206

Phenytoin  
 for alcohol withdrawal, 1207  
 for cranial neuralgia, 983

Phlebitis, antibiotic-induced, 177

Phobia, social. *See* Social anxiety disorder.

Phosphorous abnormalities, in  
 postoperative kidney dysfunction, 1248–1249

Phototoxicity, antibiotic-induced, 159–160

Physical therapy, for headache, 1082

Pimozide, for Tourette syndrome, 749

Piperacillin  
 for nosocomial pneumonia, 101, 103  
 resistance to, 20–22

Pituitary apoplexy, headache in, 978

Placenta, abruptio of, disseminated intravascular coagulation in, 1292

Placenta previa, disseminated intravascular coagulation in, 1292

Plasmapheresis, for acquired factor VIII inhibitors, 1302

Platelet(s)  
 dysfunction of  
   antibiotic-induced, 150, 152, 155  
   drug-related, postoperative bleeding in, 1281–1282  
   transfusions of, for postoperative bleeding, 1281, 1297

Pleural effusions  
 antibiotic-induced, 168  
 in pneumonia, 1389

Pneumococcal pneumonia. *See* *Streptococcus pneumoniae* pneumonia.

*Pneumocystis carinii* pneumonia  
 nonresolving, 1517  
 radiology of, 1470

Pneumonia  
 aspiration  
   in elderly persons, 1444  
   treatment of, 53  
   versus community-acquired pneumonia, 1525

community-acquired, 43–78  
 clinical features of, 1382  
 assessment of, for discharge, 1430–1431  
 definition of, 43, 1382  
 diagnosis of, 43–50, 1381–1396  
   antigen studies in, 1387–1388  
   atypical, 46–49  
   blood culture in, 1386  
   bronchoscopy in, 1390–1391

## Pneumonia (Continued)

- differentiation from nosocomial pneumonia, 1382
- for severity assessment, 1382–1383
- lung biopsy in, 1391
- methods for, 1383–1384
- polymerase chain reaction in, 1388
- recommendations for, 1392
- serologic, 1387
- sputum culture in, 1386–1387
- sputum gram stain in, 1384–1386
- thoracentesis in, 1389
- transtracheal aspiration in, 1389–1390
- transtracheal needle aspiration in, 1391
- typical, 43–45
- epidemiology of, in elderly persons, 1442
- hospital admission decisions in, 1397–1411
- mimics of, 46
- nonresolving, 1511–1530
  - atypical pathogens in, 1514
  - definition of, 1513
  - evaluation of, 1517–1518
  - fungal, 1515–1516
  - host factors in, 1511–1513
  - Legionella*, 1514
  - Mycoplasma pneumoniae*, 1514
  - Pneumocystis carinii*, 1517
  - Staphylococcus aureus*, 1513
  - tuberculosis, 1514–1515
  - unusual organisms in, 1517
  - viral, 1516–1517
- pathogens causing, 43–44, 1349–1365
  - See also specific pathogens.*
  - atypical, 1349–1365, 1502–1503
  - prediction rules and practice guidelines for, 1398–1409, 1427–1428, 1493–1509
  - American Thoracic Society, 1400–1401, 1495, 1499–1501
  - antibiotic-specific issues in, 1501–1506
  - British Thoracic Society, 1400, 1495–1496
  - Canadian, 1497–1499
  - Centers for Disease Control, 1497
  - clinical implementation of, 1405–1408
  - components of, 1493–1494
  - European Respiratory Society, 1496
  - Infectious Diseases Society of America, 1496–1499
  - new, 1497–1501
  - patient preferences and, 1407
  - physician attitudes toward, 1407, 1409
  - Pneumonia Care Process Model, 1401–1403
- Pneumonia Severity of Illness Index, 1403–1405
- use of, outcome in, 1506–1507
- prevention of, in elderly persons, 1453–1454
- severe, 1413–1425
  - assessment of, 1416, 1418, 1420–1422
  - clinical features of, 1416, 1418–1420
  - criteria for, 1419–1420
  - pathophysiology of, 1413–1416
  - prognosis for, 1416–1417
  - treatment of, 1415
- Streptococcus pneumoniae*. *See Streptococcus pneumoniae* pneumonia.
- treatment of, 50–71, 1493–1509
  - antibiotic selection for, 50–51
  - atypical, 1502–1503
  - bacteriostatic versus bactericidal agents in, 57–58
  - clinical pathways for, 1434
  - costs of, 64, 66–69
  - discharge process in, 1434–1436
  - duration of, 71
  - failure of, 71
  - for early discharge, 1427–1440
  - guidelines for, 1493–1509
  - hospital admission decisions in, 1397–1411
  - in elderly persons, 142
  - intravenous-to-oral switch in, 70, 1429–1434
  - length of stay versus quality of care in, 1428–1429
  - minimal inhibitory concentration drift in, 59–60
  - monotherapy versus combination therapy in, 63–65
  - oral, 116–117
  - outpatient, 1436
  - pharmacodynamic considerations in, 57
  - quality improvement programs in, 1434–1436
  - resistance potential in, 58–59
  - severity factors in, 56
  - side effects of, 60–62
  - spectrum of coverage in, 51–56
  - switch therapy in, 1429–1434
  - timeliness of, 1502
  - versus severity, 1427–1428
    - with multiple pathogens, 56
  - vaccines for, 1453–1454, 1531–1544
  - eosinophilic, 1522
  - fungus, radiology of, 1481–1488
  - host defense in, 1329–1347
    - in elderly persons. *See Elderly persons*
    - pneumonia in
  - interstitial, radiology of, 1468–1473
  - lipoid, 1525–1526
  - lobar, radiology of, 1462–1465

mimics of, 1519–1527  
 acute sickle chest syndrome, 1525, 1527  
 aspiration pneumonia, 1525  
 bronchial neoplasia, 1520–1522  
 bronchiolitis obliterans organizing pneumonia, 1519–1520  
 community-acquired, 46  
 drug-induced infiltrates, 1524–1525  
 eosinophilia pneumonia, 1522  
 lipid pneumonia, 1525–1526  
 lupus pneumonitis, 1523  
 nosocomial, 81–82  
 occupational lung diseases, 1527  
 pulmonary alveolar proteinosis, 1524  
 radiation pneumonitis, 1527  
 sarcoidosis, 1524  
 vasculitis, 1522–1523

nosocomial, 79–113. *See also* Pneumonia, ventilator-associated.  
*Acinetobacter*, 93–94, 1585  
 anaerobic, 95–97  
*Bacteroides*, 95–96  
 culture studies of, 82–84  
 definition of, 79–80  
 device-associated risk factors for, 1550, 1554–1557  
 diagnosis of, 79–84, 1565–1581  
 duration of, 105–106  
 early versus late, 91–93  
 epidemiology of, 1546  
   in elderly persons, 1442–1443  
 host factors in, 1551–1552  
 in host defense defects, 1340  
 incidence of, 1583  
*Klebsiella pneumoniae*, 84–85, 98, 1585  
*Legionella*, 94, 1548, 1586  
 medication-associated risk factors for, 1550, 1553–1554  
 mimics of, 81–82  
 mortality in, 1583–1584  
 necrotizing, 84–93  
 nonfermentative aerobic gram-negative bacilli in, 94  
 nonpathogens in, 94–96  
 outbreaks of, 93–94  
 pathogenesis of, 1584  
 pathogens causing, 1547–1548, 1584–1586. *See also specific pathogens.*  
   in elderly persons, 1448  
   multiple, 89, 97  
 pathophysiology of, 1546–1547  
 prevention and prophylaxis of, 1454–1455, 1548–1553  
*Pseudomonas aeruginosa*. *See* *Pseudomonas aeruginosa* infections, pneumonia.  
 risk factors for, 1545–1563  
 prophylactic measures based on, 1548–1553

*Staphylococcus aureus*, 84–88, 94–97, 1584–1585  
 treatment of, 96–106, 1583–1594  
   empiric, 96–97, 101–105, 1586–1589  
   monotherapy versus combination therapy, 97–100  
 resistance development in, 1589–1590  
 response to, 1590–1591

local, radiology of, 1462–1465  
 postoperative, fever in, 1147–1148  
 radiology of, 1461–1491  
 silent, in elderly persons, 1446  
 ventilator-associated, 1565–1581  
   colonization in, 1556–1557  
   diagnosis of  
    clinical, 1567–1568  
    clinical scenario and, 1576–1577  
    invasive sampling for, 1574–1576  
    methods for, 1565–1566  
    microbiological testing in, 1568–1574  
    noninvasive sampling for, 1574–1576  
*Pseudomonas aeruginosa*, 39  
 treatment of, 1566–1567  
 discontinuation of, 1572–1574  
 inappropriate, 1566, 1571–1572  
 microbiological testing effects on, 1570–1574  
 withholding pending culture results, 1569–1570

viral  
   nonresolving, 1516–1517  
   radiology of, 1470–1473

Pneumonia Care Process Model, prediction rules and practice guidelines for, 1401–1403

Pneumonia Severity of Illness Index, prediction rules and practice guidelines for, 1403–1405

Polydipsia, psychogenic, in schizophrenia, 679

Polymerase chain reaction, for pneumonia  
   diagnosis  
   atypical, 1357  
   community-acquired, 1388

Polymorphic ventricular tachycardia. *See* Ventricular tachycardia, polymorphic.

Positron emission tomography  
   in anxiety disorders, 558–559, 700  
   in obsessive-compulsive disorder, 738

Postoperative medical complications  
   after joint arthroplasty, 1101–1107  
   alcohol withdrawal, 1191–1212  
   cardiac, 1151–1169  
    arrhythmias, 1171–1189  
    coagulopathy, 1227–1310  
    in anticoagulant therapy, 1109–1116  
    delirium, 1229–1239  
    fever, 1141–1149  
    in diabetes mellitus, 1213–1228

Postoperative medical complications (Continued) prevention of, 521  
 long-term medication use and, 1117-1128  
 nutritional support in, 1255-1262  
 pulmonary, 1129-1139  
 renal insufficiency, 1241-1254  
 steroid-related, 1311-1317  
 stroke, 1263-1276  
 thromboembolism, 1101-1107

Postpartum depression, 639

Posttraumatic headache, 978, 987-996  
 classification of, 987  
 clinical features of, 988-989  
 differential diagnosis of, 991-992  
 epidemiology of, 988  
 pathophysiology of, 989-991  
 treatment of, 992-994, 1065

Posttraumatic stress disorder, definition of, 585

Postural hypotension. *See* Syncope, in autonomic dysfunction.

Postural orthostatic tachycardia syndrome, 463, 478-479

Preconscious information processing, in obsessive-compulsive disorder, 740

Prednisone, for acquired factor VIII inhibitors, 1302

Preexcited tachycardia  
 catheter ablation of, 484-490  
 wide QRS complex, 249-250

Prefrontal cortex, dorsolateral, pathology of, in schizophrenia, 669-671

Pregnancy  
 depression in, 639  
 disseminated intravascular coagulation in, 1292  
 headache in, neuroimaging in, 867-868  
 stroke in, 1272

Premature beats, atrial, in elderly persons, 527-529

Premenstrual syndrome, migraine in, 1017

Premonitory urges, in Tourette syndrome, 743

*Prevotella melaninogenica* pneumonia, nosocomial, 1585

Primary Care Evaluation of Mental Disorders, 581  
 in anxiety disorders, 586  
 in depression, 582-583

Proarrhythmia, 503-526  
 antiarrhythmic drug initiation monitoring for, 519-523  
 atrial, 511-513  
 bradyarrhythmias, 511  
 cardiac arrest, 510-511  
 definition of, 503-505  
 long Q-T syndrome, 326  
 mortality in, 516-517  
 pharmacokinetics of, 519  
 predictors of, 517-518

prevention of, 521  
 timing of, 505-506

torsades de pointes, 507, 509-510  
 treatment of, 521-523

ventricular tachycardia  
 in supraventricular tachycardia, 513  
 incessant, 507-508  
 incidence of, 513-515  
 new-onset, sustained, monomorphic, 506  
 sustained with increased frequency, 506

wide QRS complex tachycardia, 250

Procainamide  
 cardiac arrest due to, 510-511  
 for atrial fibrillation, 234  
 for supraventricular tachycardia, 214-217  
 for wide QRS complex tachycardia, 263  
 ventricular proarrhythmia due to, 515

Procaine penicillin, for pneumonia, *Streptococcus pneumoniae*, 1374-1375

Prochlorperazine, for migraine, 982

Progesterone, migraine related to. *See* Migraine, hormone-related.

Propafenone  
 for atrial fibrillation, 234-235, 1174  
 for supraventricular tachycardia, 214-217  
 for ventricular tachycardia, 275

Propranolol  
 for migraine  
 in pediatric patients, 1050  
 triptan interactions with, 963  
 with behavioral treatment, 1066  
 for myocardial ischemia prevention, 1159  
 for social anxiety disorder, 723  
 for supraventricular tachycardia, 216  
 for ventricular tachycardia, 278, 541

Propylthiouracil, long-term use of, perioperative recommendations for, 1125

Prospective Payment System Quality of Care Study, for primary care of psychiatric disorders, 600

Prostaglandins, in menstrual migraine pathogenesis, 1021

Prostatectomy, bleeding after, 1289-1290

Prosthetic heart valves, anticoagulant therapy for, perioperative recommendations for, 1112

Protamine, for heparin reversal, 1273, 1285-1286

Protein C deficiency, postoperative stroke in, 1265-1266

Protein S deficiency, postoperative stroke in, 1265-1266

*Proteus* pneumonia, radiology of, 1464

Prothrombin complex concentrates  
 disseminated intravascular coagulation due to, 12%

for postoperative bleeding, 1302  
*Pseudomonas aeruginosa* infections, 19-42  
 aminoglycosides for, 36-38  
 antibiotic selection for, 38-40  
 aztreonam for, 29  
 carbapenems for, 29-33  
 cephalosporins for, 26-28  
 ciprofloxacin for, 33-35  
 penicillins for, 19-25  
 pneumonia, 38-39, 84-85, 89-91, 98, 100-105  
 community-acquired, severe, 1414  
 nosocomial, 1585  
 radiology of, 1466  
 treatment of, in elderly persons, 1452  
 quinolones for, 33-36  
*Pseudomonas pseudomallei* pneumonia, nonresolving, 1517  
*Pseudotumor cerebri*, antibiotic-induced, 166  
 Psittacosis, differential diagnosis of, 48-49  
 Psychiatric disorders  
 acute, integrated medical psychiatry unit for, 609  
 Alzheimer's disease, 803-817  
 anxiety. *See Anxiety disorders*.  
 attention-deficit/hyperactivity disorder, 744, 757-777  
 bipolar disorder. *See Bipolar disorder*.  
 classification systems for, 580-581  
 depression. *See Depression*.  
 diagnosis of, 579-596  
 primary care services for, 597-616  
 drugs for, perioperative recommendations for, 1126  
 dysthymia, 631-644  
 epidemiology of, 580  
 headache with, evaluation of, 1061-1063  
 in syncope, 441-442  
 obsessive-compulsive disorder. *See Obsessive-compulsive disorder*.  
 pathophysiology of, 559-577  
 personality disorders, 714, 819-837  
 primary care services for, 597-616  
 advantages of, 599  
 collaborative models for, 604-609  
 education for, 602-604  
 integrated medical psychiatry units, 609-610  
 need for, 597-598  
 outpatient, 598-601  
 problems with, 599-601  
 screening, 601  
 status of, 598-601  
 training trends in, 610  
 treatment guidelines, 602  
 psychotherapy for. *See Psychotherapy*.  
 schizophrenia. *See Schizophrenia*.  
 screening for, 601  
 substance abuse. *See Alcohol use and abuse*; *Substance abuse*.

Tourette syndrome, 742-749  
 treatment of  
 collaborative models for, 604-609  
 consultation model for, 604-607  
 primary care services for, 597-616  
 underdiagnosis of, 580  
 Psychodynamic model, of psychotherapy, 618-619  
 Psychosis  
 antibiotic-induced, 166  
 differential diagnosis of, 667-668  
 in Alzheimer's disease, treatment of, 810-813  
 in schizophrenia, 663-666  
 Psychosocial treatment, for generalized anxiety disorder, 703  
 Psychotherapy, 617-629  
 as adjunctive treatment, 622-624  
 as first-line treatment, 624-626  
 behavioral, 619  
 cognitive behavioral, 619-620  
 educational role of, 621  
 family, 620-621  
 for bipolar disorder, 622  
 for depression, 625-626, 638  
 for medication compliance, 621-622  
 for obsessive-compulsive disorder, 624  
 for panic disorder, 625  
 for schizophrenia, 622-624, 675  
 for social anxiety disorder, 725  
 group, 620-621  
 interpersonal, 620  
 marital, 620-621  
 psychodynamic model of, 618-619  
 Pulmonary alveolar proteinosis, versus pneumonia, 1524  
 Pulmonary complications, postoperative, 1129-1139  
 case study of, 1132-1134  
 preoperative assessment for, 1134-1136  
 risk factors for, 1130-1132  
 treatment of, 1136-1137  
 Pulmonary disorders. *See also Pneumonia*.  
 antibiotic-induced, 162-163, 168  
 Pulmonary drugs, long-term use of, perioperative recommendations for, 1122-1123  
 Pulmonary embolism, postoperative, prophylaxis for, 1101-1107  
 Pure autonomic failure, syncope in, 461-462  
 Purpura, posttransfusion, 1288-1289  
 Pyridostigmine, long-term use of, perioperative recommendations for, 1125  
 Q fever, differential diagnosis of, 48-49  
 Q-T interval  
 prolonged. *See Long Q-T syndrome*.

Q-T interval (*Continued*)  
 sensing of, in pacemakers, 402  
 Quality improvement  
   for community-acquired pneumonia treatment, 1434–1436  
   for psychiatric care, 602–604  
 Quality of life, pacemaker effects on, 391, 394–396  
 Quetiapine, for schizophrenia, 675–676  
 Quinidine  
   cardiac arrest due to, 510–511  
   for atrial fibrillation, 234  
   for supraventricular tachycardia, 217  
   long Q-T syndrome due to, 326  
   torsades de pointes due to, 507, 509, 517  
   ventricular proarrhythmia due to, 515, 518  
 Quinolones. *See* Fluoroquinolones; *specific antibiotics*.  
 Quinupristin-dalfopristin  
   for coagulase-negative staphylococcal infections, 12  
   for elderly persons, 141  
   for staphylococcal infections, 6  
   for *Staphylococcus aureus* infections, 7–8  
 Radiation pneumonitis, versus pneumonia, 1527  
 Radiofrequency catheter ablation. *See* Catheter ablation.  
 Radiology, of pneumonia, 1461–1491  
   aspiration, 1467  
   bronchopneumonia, 1465–1467  
   *Escherichia coli*, 1467  
   focal, 1462–1465  
   fungal, 1481–1488  
   *Haemophilus influenzae*, 1466–1467  
   in elderly persons, 1449  
   interstitial, 1468–1473  
   *Klebsiella pneumoniae*, 1463–1464  
   *Legionella*, 1464–1465  
   lobar, 1462–1465  
   *Moraxella catarrhalis*, 1467  
   *Morganella*, 1464  
   *Mycoplasma pneumoniae*, 1468–1469  
   nonresolving. *See* Pneumonia, community-acquired, nonresolving.  
   nontuberculous mycobacterial, 1480–1481  
   *Pneumocystis carinii*, 1470  
   *Proteus*, 1464  
   *Pseudomonas aeruginosa*, 1466  
   *Staphylococcus aureus*, 1465–1466  
   *Streptococcus pneumoniae*, 1462  
   *Streptococcus pyogenes*, 1466  
   tuberculous, 1473–1480  
   viral, 1470–1473  
 Rage attacks, in Tourette syndrome, 749  
 Raloxifene, for migraine, 1026  
 Rash, antibiotic-induced, 157–158  
 Rat poisons (superwarfarins),  
   postoperative bleeding due to, 1286  
 Reality distortion, in schizophrenia, 665–666  
 Reboxetine, for depression, 637  
 Red neck syndrome and red man syndrome, antibiotic-induced, 157–158  
 Reentry  
   in atrioventricular node reentrant tachycardia, 197–204  
   in ventricular tachycardia, 269–270, 284–286  
 Relaxation training  
   for generalized anxiety disorder, 703  
   for headache, 1063–1065  
   for social anxiety disorder, 725  
 Resistance, antibiotic. *See* Antibiotics, resistance to.  
 Respiratory disorders. *See* Pneumonia; Pulmonary complications.  
 Respiratory therapy, equipment for, nosocomial pneumonia due to, 1557  
 Retinopathy, diabetic, postoperative considerations in, 1216–1217  
 Rhabdomyolysis  
   antibiotic-induced, 179  
   in postoperative kidney dysfunction, 1249  
*Rhodococcus equi* pneumonia, nonresolving, 1517  
 Riboflavin, for migraine, 1081  
 Rifampin  
   for coagulase-negative staphylococcal infections, 12  
   for elderly persons, 151  
   pulmonary side effects of, 162  
 Right ventricular outflow tract ventricular tachycardia, 288–289, 306–307  
 Rimantadine, for influenza pneumonia prophylaxis, 1454, 1539–1541  
 Risperidone  
   for Alzheimer's disease, 812–813  
   for schizophrenia, 675  
   for Tourette syndrome, 749  
 Rituximab, for acquired factor VIII inhibitors, 1302  
 Rivastigmine, for Alzheimer's disease, 805–806  
 Rizatriptan  
   for migraine, 962  
   in pediatric patients, 1043–1045  
   safety of, 963  
   structure of, 955  
 Rofecoxib, long-term use of, perioperative recommendations for, 1119–1120  
 Romano-Ward syndrome, long Q-T interval in, 334

Sagittal venous sinus, thrombosis of, headache in, 977-978

Salmonellosis, treatment of, 121

Sarcoidosis

- pulmonary, versus pneumonia, 1524
- ventricular tachycardia in, 298

Scalded skin syndrome, treatment of, 119

Scarlet fever, treatment of, 119

Schizoid personality disorder, 831-832

Schizophrenia, 663-689

- course of, 664-665
- differential diagnosis of, 667-668
- genetics of, 560, 669
- incidence of, 668-669
- medical illness with, 676-679
- pathophysiology of, 560-562
- neural circuitry in, 669-673
- neurochemical models of, 673-674
- phenomenology of, 665-667
- prevalence of, 663
- prodrome of, 664
- psychotherapy for, 622-624
- risk factors for, 668-669
- treatment of, 562
- pharmacologic, 674-676
- psychosocial, 676

Schizotypal personality disorder, 832

Sedatives, nosocomial pneumonia associated with, 1553

Seizures

- antibiotic-induced, 161
- in alcohol withdrawal, 1200

Selective digestive decontamination, for pneumonia prevention, 1454-1455

Selective estrogen receptor modulators for migraine, 1026

- long-term use of, perioperative recommendations for, 1124

Selective serotonin reuptake inhibitors

- for attention deficit/hyperactivity disorder, 769
- for depression, 636, 809-810
- for obsessive-compulsive disorder, 741-742
- for social anxiety disorder, 720-722, 726
- for syncope, 470
- long-term use of, perioperative recommendations for, 1125

Selegiline

- for social anxiety disorder, 722
- long-term use of, perioperative recommendations for, 1125

Sensing, by defibrillator, 346-349

Sensory disorders, in migraine, 899, 945, 947-948

Sensory stimuli, as migraine triggers, 906-907

Sepsis

- catheter-related, in nutritional support, 1260

disseminated intravascular coagulation

- in, 1291
- fever in, 1143

Septic abortion, disseminated intravascular coagulation in, 1292

Sequential therapy, 1429-1430

Serotonin, abnormalities of

- in anxiety disorders, 565-566, 699
- in depression, 632-633
- in obsessive-compulsive disorder, 739
- in schizophrenia, 670

Serotonin reuptake inhibitors. *See* Selective serotonin reuptake inhibitors

Serotonin syndrome, triptan-induced, 961, 963

Serratia pneumonia, nosocomial, 1585

Sertraline

- for depression, 636
- for social anxiety disorder, 721

Serum sickness, antibiotic-induced, 159-160

Severe combined immunodeficiency, pneumonia risk in, 1341, 1343

Sexual activity, headache in, 1085-1086

*Shigella* gastroenteritis, treatment of, 122

Shock liver, disseminated intravascular coagulation in, 1291, 1295

Shy-Drager syndrome, syncope in, 462-463

Shyness, versus social anxiety disorder, 714

Sick headache, 951

Sick sinus syndrome. *See* Sinus node, dysfunction of

Sickle cell disease, acute chest syndrome in, versus pneumonia, 1525, 1527

SIGECAPS mnemonic, for depression symptoms, 632

Single-photon computed tomography, in anxiety disorders, 568-569, 700

Sinopulmonary infections, antibiotics in, 116-117

Sinus bradycardia, as proarrhythmia, treatment of, 522-523

Sinus node

- dysfunction of
- pacemaker in, 371, 389-400
- perioperative, 1181-1182
- supraventricular tachycardias originating in, 206, 209

Sinus rhythm

- maintenance of, in atrial fibrillation, 233-239
- restoration of, in atrial fibrillation, 231-233

Sinus tachycardia

- inappropriate, 206, 209, 478-479
- perioperative, 1172, 1176

Sinusitis, nosocomial pneumonia risk in, 1555

Skin infections, antibiotics for, 118-120

- in elderly persons, 142-143

Sleep disturbances, as migraine triggers, 919-920

Smoking, 790-791

- as migraine trigger, 922-923
- in schizophrenia, 679
- screening for, 591-592

Sneeze headache, 1085-1086

Social anxiety disorder, 711-733

- classification of, 711-712
- clinical features of, 712-713
- comorbidity with, 719, 725-726
- consequences of, 719
- diagnosis of, 714-717
- differential diagnosis of, 713-714
- generalized, 713
- nongeneralized, 713
- pathophysiology of, 715, 718-719
- prevalence of, 712
- subtypes of, 713
- treatment of
  - behavioral, 724
  - future, 725
  - long-term, 724
  - new research applications to, 725-727
  - pharmacologic, 720-724
  - psychotherapy, 725
  - social skills training, 724

Social skills training

- in schizophrenia, 623
- in social anxiety disorder, 724

Sodium, fractional excretion of, in

- postoperative kidney dysfunction, 1246-1247

Sotalol

- for atrial fibrillation, 234, 1174
- for supraventricular tachycardia, 214-217
- for ventricular tachycardia, 274, 278
- proarrhythmia monitoring and, 520

Sparfloxacin, photosensitivity due to, 160

Spasticity, antibiotic-induced, 161, 165, 166

Spreading depression phenomenon, in

- migraine, 913, 951

Sputum testing, in pneumonia

- antigen studies, 1387-1388
- culture, 1386-1387
- Gram stain, 1384-1386
- polymerase chain reaction, 1388

Stair climbing test, in postoperative

- pulmonary risk prediction, 1135-1136

Standing, syncope related to. *See* Syncope, in autonomic dysfunction.

Staphylococcal infections, coagulase-negative, 9-13

- antibiotics in, 11-13
- resistance in, 10-11
- types of, 9-10

*Staphylococcus aureus* infections, 1-9

- antibiotics in, 5-9
- osteomyelitis, 117

pneumonia, 84-88, 94-97

- community-acquired, severe, 1414
- nosocomial, 1548, 1584-1585
- radiology of, 1465-1466

resistance in, 127

- b-lactam, 2-3
- glycopeptide, 3-5
- skin, 118-120
- types of, 1-2

*Staphylococcus epidermidis* infections, 9-13

- antibiotics in, 11-13
- resistance in, 10-11
- types of, 9-10

Statins, long-term use of, perioperative recommendations for, 1122

Status migrainosus, 907

Steatoisis, hepatic, in nutritional support, 1260-1261

Step-down therapy, 1429-1430

Stevens-Johnson syndrome, antibiotic-induced, 157, 159

Stimulants

- abuse of, 780-783
- for attention deficit/hyperactivity disorder, 766-768

Stomatitis, antibiotic-induced, 179

Streamlining therapy, 1429-1430

Streptococcal cellulitis, treatment of, 119

*Streptococcus pneumoniae* pneumonia, 43-45

- community-acquired, 1367-1379
- antibiotic-resistant, 1367-1368, 1503-1504
- empirical therapy for, 1374-1376
- epidemiology of, 1368-1369
- outcome of, 1371-1374
- risk factors for, 1369-1371
- severe, 1414
- epidemiology of, 1368-1369, 1531-1532
- in elderly persons, 1447-1448
- nonresolving, 1513
- nosocomial, 1547-1548, 1584-1585
- radiology of, 1462
- treatment of
  - bacteriostatic versus bactericidal, 57-58
  - empiric, 52-53, 55-56
  - in elderly persons, 1451
  - minimal inhibitory concentration drift in, 58-60
  - monotherapy versus combination therapy in, 63-66
  - resistance in, 58-59
- vaccines for, 1453-1454, 1531-1535

*Streptococcus pyogenes* pneumonia, radiology of, 1466

Streptogramins, for *Staphylococcus aureus* infections, 7-8

Streptokinase, postoperative bleeding due to, 1286-1287

Stress

- as migraine trigger, 918-919

assessment of, for behavioral treatment, 1060

autonomic response to, in anxiety disorders, 699–700

perioperative, hypothalamic-pituitary-adrenal axis function in, 1312–1313

Stroke

- headache in, 977
- in oral contraceptive use, 1028–1029
- postoperative, 1263–1276
  - epidemiology of, 1263
  - evaluation of, 1272–1273
- hemorrhagic, mechanisms of, 1270–1272
  - in cardiac disease, 1264–1265
  - in fat embolism, 1265
  - in hematologic disorders, 1270–1271
  - in hypercoagulopathy, 1265–1267
  - in neurosurgical procedures, 1271
  - in obstetric procedures, 1272
  - in vasculitis, 1267, 1270
  - ischemic, mechanisms of, 1263–1269
  - surgical procedures associated with, 1267–1269
  - treatment of, 1272–1273
- triptan-induced, 965

Structured Clinical Interview for DSM, for psychiatric disorder screening, 601

Subarachnoid hemorrhage, headache in, 850–851, 1086–1087

diagnosis of, 873–878

emergency department handling of, 976–977

Subclavian crush syndrome, in defibrillator implantation, 352

Substance abuse, 779–801. *See also* Alcohol use and abuse.

- anxiety disorder in, 585
- clinical features of, 591
- cocaine, 780–783
- diagnosis of, 587–592
- in bipolar disorder, 654
- nicotine, 591–592, 790–791
  - in schizophrenia, 679
- opioids, 787–789
- prescription drugs, 794–796
- recreational drugs, 791–794
- schizophrenia with, 678–679
- versus depression, 634
- versus schizophrenia, 667

Suffocation alarm model, in anxiety disorders, 567

Suicide

- in depression, 584, 635
- in social anxiety disorder, 719

Sumatriptan

- for cluster headache, 982–983, 999
- for migraine, 962–965
  - in pediatric patients, 1043–1044
  - menstrual, 1023

safety of, 962

structure of, 955

SUNCT syndrome, 1006–1008, 1010

Superwarfarins, postoperative bleeding due to, 1286

Supraventricular tachycardia, 193–223

- arising from sinus node region, 206, 209
- atrial tachycardia, 201, 203, 205–207
- atrioventricular node reentrant tachycardia, 194–197
  - mediated by accessory pathways, 197–204
- classification of, 193–194
- clinical features of, 209–210
- differential diagnosis of, 210–213
- in elderly persons, 527–532
- junctional tachycardia, 206
- mechanisms of, 194–209
- multifocal atrial tachycardia, 206, 208
- pacemaker in, 372
- paroxysmal, perioperative, 1178–1179
- treatment of, 213–220
  - ventricular proarrhythmia in, 513–515
- wide QRS complex, 248–251

electrocardiography of, 252–253, 255, 257

Surfactant, in respiratory infection defense, 1332

Switch therapy, 70

- for pneumonia, 1429–1434

Sympathetic ganglionectomy, for long Q-T syndrome, 336

Syncope, 423–456

- arrhythmic, treatment of, 449–450
- causes of, 424
- definition of, 423–424
- diagnosis of, 425–445
  - algorithms for, 443–445
  - carotid sinus massage in, 440–441
  - echocardiography in, 429–430
  - electrocardiography in, 429–435
  - electrophysiologic, 435–436
  - exercise tolerance testing in, 430
  - history in, 427–428
  - Holter monitoring in, 430–431
  - laboratory testing in, 429
  - loop recorders in, 433–434
  - neurologic studies in, 436–437
  - physical examination in, 428–429
  - psychiatric evaluation in, 441–442
  - tilt-table testing in, 438–440
- driving with, 447
- hospital admission in, 445–446
- in autonomic dysfunction, 457–472
  - acute, 464
  - chronic, 461–463
  - clinical features of, 465–466
  - evaluation of, 466–467
  - pathophysiology of, 458–459
  - postural orthostatic tachycardia syndrome, 463, 478–479

**Syncope (Continued)**  
 primary, 461–464  
 reflex, 459, 461  
 secondary, 464–470  
 treatment of, 467–470  
 types of, 459–460  
 in elderly persons, 450  
 neurocardiogenic (vasovagal)  
   pacemaker in, 374–377  
   treatment of, 447–449  
 pacemaker in, 374–377, 390  
 pathophysiology of, 424  
 prognosis for, 445  
 reflex, 459–461  
 risk stratification in, 445–447  
 treatment of, 447–450

**Syndrome of inappropriate antidiuretic hormone secretion, postoperative**, 1247–1248

**Systemic inflammatory response syndrome**, fever in, 1143

**Systemic lupus erythematosus**  
 antibiotic-induced, 159–160  
 pneumonitis in, versus pneumonia, 1523

**T lymphocytes**, in respiratory infection defense, 1333–1340, 1343, 1445

**Tachycardia**  
 atrial. *See* Atrial tachycardia.  
 in postural orthostatic tachycardia syndrome, 463, 478–479  
 perioperative  
   myocardial ischemia in, 1155  
   narrow-complex, 1178–1179  
   wide-complex, 1181  
 preexcited, wide QRS complex, 249–250  
 supraventricular. *See* Supraventricular tachycardia.  
 ventricular. *See* Ventricular tachycardia.  
 wide QRS complex, 245–266

**Tachypnea**, in pneumonia, in elderly persons, 1446

Tacrine, for Alzheimer's disease, 805

Tamoxifen, for migraine, 1026

Tardive dyskinesia, in antipsychotic agent therapy, 674–675

Teichopsia, in migraine, 945

Teicoplanin  
 for staphylococcal infections, 6–7, 12  
 resistance to, 3–5, 11

Temporal arteritis, headache in, 879–882, 980, 1087–1088

Temporal artery, dilation of, in migraine, 948–949

Temporal lobe, medial, pathology of, in schizophrenia, 672–673

Temporomandibular joint dysfunction, pain in, 989, 1087

Tendinitis, antibiotic-induced, 177, 179

**Tension-type headache**  
 chronic, 903–905  
 epidemiology of, 890  
 episodic, 903–905  
 impact of, 891–892  
 treatment of  
   behavioral, 1065–1067  
   emergency, 982  
 versus migraine without aura, 903–906

**Tetracyclines. *See also* Doxycycline;**  
 Minocycline.  
 for *Campylobacter* gastroenteritis, 122  
 for cholera, 122  
 for pneumonia  
   atypical, 1359  
   *Streptococcus pneumoniae*, 1368  
 hepatotoxicity of, 173  
 minimal inhibitory concentration drift of, 59–60  
 new uses of, 125–127  
 resistance to, 3, 10

**Thalamus**, pathology of, in schizophrenia, 671

**Theophylline**, long-term use of, perioperative recommendations for, 1122–1123

Thiabendazole, hepatotoxicity of, 173

Thioridazine, for Alzheimer's disease, 811

Thiothixene, for Alzheimer's disease, 811

Thoracentesis, for pneumonia diagnosis, community-acquired, 1389

**Thoracic surgery**, arrhythmias related to, 1174–1175

**Thoracoscopy**, for lung biopsy, in pneumonia, 1391

Thrombin, excess of, in disseminated intravascular coagulation, 1290–1291

**Thrombocytopenia**  
 antibiotic-induced, 150, 155  
 heparin-induced, postoperative, 1283–1284, 1305–1307  
 in massive blood transfusions, 1288  
 postoperative bleeding in, 1307–1308  
 postoperative stroke in, 1270

**Thrombocytosis**, antibiotic-induced, 155

**Thromboembolism**, prevention of, in atrial fibrillation, 231–233

**Thrombolytic therapy**  
 for myocardial infarction, 1159–1160  
 postoperative bleeding due to, 1286–1288

**Thrombosis**  
 deep vein. *See* Deep vein thrombosis.  
 in disseminated intravascular coagulation, 1290–1291  
 risks of, in anticoagulant discontinuation, 1111–1112, 1114–1115

**Thunderclap headache**, 976, 1086–1087

**Thyroid hormones**, long-term use of, perioperative recommendations for, 1125

Tic douloureux, treatment of, 983

Tic syndromes, with cluster headaches, 1008-1010

Ticarcillin, for *Pseudomonas aeruginosa* infections, 25

Ticlopidine, postoperative bleeding due to, 1281-1282

Tics. *See also* Tourette syndrome. types of, 742-743

Tilt-table testing, in syncope, 438-440

Tinzaparin, postoperative bleeding due to, 1285

Tirofiban, postoperative bleeding due to, 1282

Tissue-plasminogen activator, postoperative bleeding due to, 1287

Torsades de pointes

- acquired, 325-327
- as proarrhythmia, 507, 509-510, 522
- cellular mechanisms of, 327-329
- definition of, 322-323
- evaluation of, 332
- in long Q-T syndrome, 291-294
- pacemaker in, 377-379
- short-coupled variant of, 323
- treatment of, 329-332, 522

Tourette syndrome, 742-749

- comorbidity with, 744
- cyclic nature of, 748
- diagnosis of, 742-744
- genetics of, 747-748
- internal world of, 743
- neuroimaging in, 745-746
- obsessive-compulsive disorder with, 743-744
- pathophysiology of, 744-747
- treatment of, 748-749
- versus obsessive-compulsive disorder, 735, 737

Toxic shock syndrome, treatment of, 119

TPN liver (hepatic steatosis), 1260-1261

Tranexamic acid, for postoperative bleeding, 1287

Transferrin, carbohydrate-deficient, in alcohol abuse screening, 590-591

Transfusions, postoperative bleeding related to, 1288-1289

Transient ischemic attack

- headache in, 977
- versus migraine, 898

Transplantation

- heart, pacemaker in, 373
- pneumonia risk in, 1341

Transthoracic aspiration, for pneumonia diagnosis, 1390-1391

Transtracheal aspiration, for pneumonia diagnosis, community-acquired, 1389-1390

Tranylcypromine for bipolar disorder, 657

for social anxiety disorder, 722-723

Trauma, disseminated intravascular coagulation in, 1293-1294

Trazodone, for generalized anxiety disorder, 705

Tremors, antibiotic-induced, 161, 166

Tricyclic antidepressants

- for attention deficit/hyperactivity disorder, 768-769
- for depression, 637
- for social anxiety disorder, 723-724
- long-term use of, perioperative recommendations for, 1125

Trifascicular block, pacemaker in, 370

Trigeminal nerve

- activation of, in migraine, 913-914
- neuralgia of

  - cluster headache with, 1009
  - treatment of, 983

Triggers

- of migraine. *See also* Migraine, triggers of.
- of SUNCT syndrome, 1007-1008

Trimethoprim-sulfamethoxazole

- anaphylactic reactions to, 157
- drug rash due to, 157
- for elderly persons, 140
- for listeriosis, 123
- for osteomyelitis, 117
- for staphylococcal infections, 6
- for urinary tract infections, 123
- new uses for, 127-128
- pancreatitis due to, 171
- resistance to, 10

Triptans. *See also* specific drugs.

- for migraine, 959-970, 982
- cardiovascular effects of, 964-965
- central nervous system effects of, 961
- drug interactions with, 961-964
- formulations for, 961
- in pediatric patients, 1042-1045
- mechanism of action of, 953-954, 959-960
- menstrual, 1021-1023
- onset of, 960-961
- overview of, 960-961
- rational use of, 966
- safety of, 961-965
- structures of, 955
- triptan sensations due to, 961

Trovafloxacin

- for *Pseudomonas aeruginosa* infections, 35-36
- hematologic effects of, 152
- hepatitis due to, 171
- hypotension due to, 163
- neurologic side effects of, 160-161
- pancreatitis due to, 171

Trypanosomiasis, American (Chagas' disease), ventricular tachycardia in, 299

Tuberculosis  
 radiology of, 1473–1480  
 in HIV infection, 1480  
 nonresolution of, 1514–1515  
 primary, 1473–1476  
 secondary reactivation, 1476–1480  
 treatment of, in elderly persons, 151

Tularemia, differential diagnosis of, 48–49

Tumor(s), brain  
 headache in, 978–979  
 postoperative stroke in, 1269

Tumor necrosis factor- $\alpha$ , pyrogenic effects of, 1142–1143

TWEAK questionnaire, for alcohol use screening, 589, 1194–1195

Tyramine, as migraine trigger, 927–928

Ulcers, diabetic, treatment of, 119

Ultrasonography  
 in postoperative kidney dysfunction, 1247  
 in syncope, 437

Uremic bleeding, postoperative, 1297

Urinary tract infections  
 antibiotics for, 123, 142  
 postoperative, fever in, 1147

Urine sediment examination, in postoperative kidney dysfunction, 1246

Urokinase, postoperative bleeding due to, 1287

Uterine bleeding, postoperative, 1290

Vaccines, for pneumonia, 1531–1544  
 influenza, 1535–1541  
 investigational, 1541–1542  
 pneumococcal, 1453–1454, 1531–1535

Vagal maneuvers, for paroxysmal supraventricular tachycardia, 1179

Valerian root, for headache, 1081

Valproate  
 for alcohol withdrawal, 1206  
 for bipolar disorder, 655–658  
 for cluster headache, 999  
 for migraine, 982, 1049, 1051

Vancomycin  
 for *Clostridium difficile* infections, 121  
 for elderly persons, 141  
 for osteomyelitis, 117  
 for staphylococcal infections, 6, 12  
 for *Staphylococcus aureus* infections, 5, 7  
 red man syndrome due to, 157  
 resistance to, 3–5

Varicella pneumonia  
 nonresolving, 1517  
 radiology of, 1472

Vascular system  
 in migraine, 945  
 triptan effects on, 964–965

Vasculitis  
 cerebral, postoperative stroke in, 1267, 1270  
 pulmonary, versus pneumonia, vasculitis, 1522–1523

*Veillonella parvula* pneumonia, nosocomial, 1585

Venlafaxine  
 for attention deficit/hyperactivity disorder, 769  
 for depression, 636–637  
 for generalized anxiety disorder, 705–706

Ventilator-associated pneumonia. *See* Pneumonia, ventilator-associated.

Ventricle(s)  
 resynchronization of, in congestive heart failure, 383–386  
 right, dysplasia of, tachycardia in, 296–298

Ventricular fibrillation, perioperative, 1180–1181

Ventricular premature contractions, perioperative, 1180

Ventricular tachycardia, 267–304  
 as proarrhythmia, 506, 507, 513–515  
 bundle-branch reentrant, catheter ablation of, 493  
 catecholaminergic, 296, 323, 333  
 catheter ablation of, 491–496  
 classification of, 268–269  
 electrophysiologic studies of, in elderly persons, 539–540  
 epidemiology of, 267–268  
 historical background of, 267  
 idiopathic, catheter ablation of, 492–493  
 in arrhythmogenic right ventricular dysplasia, 296–298  
 in Brugada's syndrome, 294–295, 323–324  
 in cardiomyopathy  
 hypertrophic, 286–288  
 idiopathic, 284–286  
 in Chagas' disease, 299  
 in digoxin toxicity, 296  
 in elderly persons, 535–544  
 electrophysiologic studies of, 539–540  
 prevalence of, 535–536  
 prognosis of, 535, 537–539  
 treatment of, 540–544

in ischemic heart disease, 270–283

in long Q-T syndrome, 291–294

in muscular dystrophy, 298

in myocarditis, 298

in sarcoidosis, 298

incessant, as proarrhythmia, 507

left ventricular, idiopathic, 289–291

mechanistic description of, 269–270

monomorphic, in normal heart, 288–291  
 new-onset, sustained, monomorphic, as proarrhythmia, 506  
 nonidiopathic, catheter ablation of, 493–496  
 nonsustained, 305–320  
     definition of, 305  
     in coronary artery disease, 312–315  
     in dilated cardiomyopathy, nonischemic, 311–312  
     in hypertrophic cardiomyopathy, 310–311  
     in mitral valve prolapse, 307, 309–310  
     without structural heart disease, 306–308  
 pacemaker in, 372  
 perioperative, 1180–1181  
 polymorphic, 321–341. *See also* Torsades de pointes.  
     cellular mechanisms of, 327–329  
     classification of, 322–325  
     definition of, 321–322  
     evaluation of, 332  
     in normal heart, 291–299  
     referral in, 337  
     treatment of, 329–332  
     with prolonged Q-T interval, 291–294, 325–327, 334–337  
     without prolonged repolarization, 325–332  
 prevalence of, in elderly persons, 535–536  
 prognosis of, in elderly persons, 535, 537–539  
 right ventricular outflow tract, 288–289  
 sustained with increased frequency, as proarrhythmia, 506  
 syncope in, 449–450  
 treatment of, in elderly persons, 540–544  
 unrelated to coronary artery disease, 273, 284–288  
 wide QRS complex, 247–248, 250–251  
     electrocardiography of, 252–254, 256–260  
 Verapamil  
     for atrial fibrillation, 230  
     for cluster headache, 999  
     for supraventricular tachycardia, 214–217  
     for wide QRS complex tachycardia, 262, 264  
 Vertebral artery, dissection of, headache in, 977  
 Vertebral osteomyelitis, treatment of, 117  
*Vibrio cholerae* gastroenteritis, treatment of, 122  
 Viral infections  
     pneumonia  
         nonresolving, 1516–1517  
         radiology of, 1470–1473  
     treatment of, in elderly persons, 144  
 Visual loss, in migraine, 898  
 Visual stimulus, as migraine trigger, 920–921  
 Vitamin(s)  
     for alcohol withdrawal, 1204–1205  
     for migraine, 1081  
 Vitamin E, for Alzheimer's disease, 807  
 Vitamin K deficiency, postoperative bleeding in, 1286  
 Vocal tic disorder, chronic, 742–743  
 Vomiting, antibiotic-induced, 170, 172  
 von Willebrand's disease, postoperative stroke in, 1270

Warfarin  
     for atrial fibrillation, 231–233, 531  
     for deep vein thrombosis prevention, 1102, 1104, 1106  
     for heparin-induced thrombocytopenia, 1284  
     pharmacokinetics of, 1112–1113  
     postoperative bleeding due to, 1286  
 Weather changes, as migraine triggers, 921–922  
 Wegener's granulomatosis, versus pneumonia, 1523  
 Wernicke's encephalopathy, in alcoholism, 785  
 Whiplash injury, headache with, 988–989  
 Wide-complex tachycardia, perioperative, 1181  
 Wide QRS complex tachycardia, 245–266  
     causes of, 246–250  
     classification of, 247  
     clinical assessment of, 250–262  
     definition of, 245  
     differential diagnosis of, 246–250  
     treatment of, 262–264  
 Wine, as migraine trigger, 925–926  
 Wiskott-Aldrich syndrome, pneumonia risk in, 1341, 1343  
 Withdrawal  
     alcohol, 783–786. *See also* Alcohol use and abuse, postoperative withdrawal syndrome in.  
     opioid, 787–789  
 Wolff-Parkinson-White syndrome, 197–204, 218–219  
     catheter ablation of, 484–486  
 Worry, in generalized anxiety disorder, 692, 701  
 Wound(s)  
     infection of, postoperative, fever in, 1146–1147  
     surgical hemostasis in, 1297

Xanthochromia, in subarachnoid hemorrhage, 877

Zanamivir, for influenza pneumonia  
prophylaxis, 1539-1541  
Zolmitriptan  
for migraine, 962

in pediatric patients, 1043-1045  
safety of, 963  
structure of, 955

